Note: Descriptions are shown in the official language in which they were submitted.
WO 2022/260723
PCT/US2022/015217
INDUCED EXTRA VASATION BY ENERGY DELIVERY TO TISSUE
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit of U.S.
Provisional Patent Application No.
63/209,335, filed June 10, 2021, entitled "Induced Extravasation by Energy
Delivery to Tissue", and is a
U.S. continuation-in-part of PCT/U52021/044469, filed on August 4, 2021,
entitled "PULSED
ELECTRIC FIELD TRANSFER OF MOLECULES TO CELLS WHILE IN THE BODY" which claims
priority to and the benefit of U.S. Provisional Patent Application No.
63/061,114, filed August 4, 2020,
entitled "Enhanced Transfer with Pulsed Electric Fields-, U.S. Provisional
Patent Application No.
63/061,091, filed August 4, 2020, entitled "Pulsed Electric Fields in the
Eye", and U.S. Provisional Patent
Application No. 63/209,335, filed June 10, 2021, entitled "Induced
Extravasation by Energy Delivery to
Tissue", the disclosures of all of the foregoing applications are incorporated
herein by reference in their
entireties.
BACKGROUND
[0002] Cells in the body regularly die off and new cells divide and
replace them when this happens.
However, when cells divide uncontrollably and serve no purpose, a mass of
tissue known as a tumor can
appear. Tumors are groups of abnormal cells that form growths or lumps. They
can start in any one of the
many cells throughout the body. Tumors grow and behave differently, depending
on whether they are
cancerous (malignant), non-cancerous (benign) or precancerous. Malignant
tumors grow beyond their
usual boundaries to invade adjoining parts of the body and/or spread to other
organs. The latter process is
called metastasizing and is a major cause of death from cancer. A neoplasm and
malignant tumor are
common names for cancer.
[0003] There are many types of cancer treatment. The types of
treatment received will depend on the
type of cancer and how advanced it is. Some people with cancer will have only
one type of treatment.
But most people have a combination of treatments, such as surgery with
chemotherapy and radiation
therapy. Chemotherapy is a type of cancer treatment that uses chemotherapeutic
agents as part of a
standardized chemotherapy regimen. Chemotherapy may be given with a curative
intent or it may aim to
prolong life or to reduce symptoms. Chemotherapy is one of the major
categories of the medical
discipline specifically devoted to pharmacotherapy for cancer, which is called
medical oncology.
[0004] Traditional chemotherapeutic agents are cytotoxic by means
of interfering with cell division
(mitosis) but cancer cells vary widely in their susceptibility to these
agents. To a large extent,
chemotherapy can be thought of as a way to damage or stress cells, which may
then lead to cell death if
apoptosis is initiated. Many of the side effects of chemotherapy can be traced
to damage to normal cells
that divide rapidly and are thus sensitive to anti-mitotic drugs: cells in the
bone marrow, digestive tract
and hair follicles. This results in the most common side-effects of
chemotherapy: myelosuppression
(decreased production of blood cells, hence also immunosuppression), mucositis
(inflammation of the
lining of the digestive tract), and alopecia (hair loss). Because of the
effect on immune cells (especially
lymphocytes), chemotherapy drugs often find use in a host of diseases that
result from harmful
-1-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
overactivity of the immune system against self (so-called autoimmunity). These
include rheumatoid
arthritis, systemic lupus erythematosus, multiple sclerosis, vasculitis and
many others.
[0005] The development of therapies with specific molecular or
genetic targets, which inhibit growth-
promoting signals from classic endocrine hormones (primarily estrogens for
breast cancer and androgens
for prostate cancer) are now called hormonal therapies. By contrast, other
inhibitions of growth-signals
like those associated with receptor tyrosine kinases are referred to as
targeted therapy. The use of drugs
(whether chemotherapy, hormonal therapy or targeted therapy) typically
constitutes systemic therapy for
cancer in that they are introduced into the blood stream and are therefore in
principle able to address
cancer at any anatomic location in the body. Systemic therapy is often used in
conjunction with other
modalities that constitute local therapy (i.e. treatments whose efficacy is
confined to the anatomic area
where they are applied) for cancer such as radiation therapy, surgery or
hyperthermia therapy.
[0006] Systemic therapy has an important role in the management of
patients diagnosed with cancer,
but the use of many of these agents is clearly associated with long-term
toxicities in long-term survivors.
Present and future challenges include appropriate delivery of cytotoxic agents
(and other components of
multimodal anti-cancer treatment regimens) to maximize therapeutic efficacy
while limiting both acute
and long-term side-effects. The sequential use of several different
chemotherapy agents is becoming
increasingly common to overcome tumor resistance as it emerges e.g., in
patients with metastatic colon
and breast cancer, and there is evidence for improved overall survival.
Nevertheless, these patients often
accumulate considerable exposure to multiple chemotherapeutic agents and are
thus at high risk of
cumulative treatment-related side-effects. Paradoxically patient ability or
willingness to tolerate such
side-effects, rather than uncontrolled disease, or absence of potential active
anti-cancer treatments, may
rapidly become the limiting factor for treatment success in this population.
[0007] Thus, improvements in therapy for cancer and other tumors
are desired. Such treatments
should be safe, effective, and lead to reduced complications. Such treatments
should also be applicable to
therapies involving transfer of various types of molecules to cells,
particularly macromolecules. At least
some of these objectives will be met by the systems, devices and methods
described herein
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] In the drawings, which are not necessarily drawn to scale,
like numerals may describe similar
components in different views. Like numerals having different letter suffixes
may represent different
instances of similar components. The drawings illustrate generally, by way of
example, but not by way of
limitation, various embodiments discussed in the present document.
[0009] Fig. 1 illustrates a tumor within a lung of a patient.
[0010] Fig. 2 schematically illustrates the pulmonary artery
distribution throughout the lungs.
[0011] Fig. 3 illustrates an endoluminal approach to the tumor
wherein a bronchoscope is advanced
through the trachea and the right mainstem bronchus toward the tumor.
-2-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[0012] Fig. 4 illustrates the distal end of the bronchoscope
advanced through the lung passageways so
as to reach the tumor.
[0013] Fig. 5A illustrates a few molecules having entered the
target tissue area while a significant
quantity remains within the blood vessels.
[0014] Fig. 5B illustrates conditioning energy delivered to the
target tissue area from the energy
delivery body as indicated by wavy lines.
[0015] Fig. 5C illustrates extravasation and a flooding of the
target tissue area with fluid and solutes,
including molecules from the blood vessels.
[0016] Fig. 6 illustrates an energy delivery body inserted in a
tumor.
[0017] Fig. 7 illustrates that what was once a tumor is now a
debris field that extends outwards to the
peripheral margin.
[0018] Fig. 8A illustrates dendritic cells and other immune cells
sweeping out (as indicated by
arrows) of the adjacent intact lung tissue and into the debris field.
[0019] Fig. 8B illustrates the dendritic cells and other immune
cells moving out (as indicated by
arrows) of the debris field and back into the surrounding lung tissue.
[0020] Fig. 9 illustrates dendritic cells and other immune cells
entering afferent lymphatic ducts.
[0021] Fig. 10 illustrates the original tumor site which is now a
debris field with nearby lymph nodes
and activated T-cells flowing from the lymph nodes.
[0022] Fig. 11 illustrates dendritic cells and other immune cells
traveling through lymphatic ducts to
lymph nodes, activated T-cells traveling to the heart, and activated T-cells
traveling to remote locations in
the body.
[0023] Fig. 12 illustrates the activated T-cells traveling to
metastatic tumors in the liver.
[0024] Fig. 13 illustrates an embodiment of an energy delivery
system for delivering energy to a
target tissue area.
[0025] Figs. 14A-14B illustrate an example waveforms of pulsed
electric field energy provided by an
energy delivery algorithm of the generator used for inducing extravasation.
[0026] Figs. 15A-15B, 16A-16B illustrate example waveforms provided
by an energy delivery
algorithm of the generator used for providing therapeutic treatment.
[0027] Fig. 17 illustrates an embodiment of a waveform configured
for oncological treatments.
[0028] Figs. 18A-18C illustrate embodiments of a pressure sensor.
[0029] Fig. 19 illustrates three example timing embodiments for
molecule delivery in relation to a
treatment delivery.
[0030] Fig. 20 provides results of a laboratory study.
[0031] Figs. 21A-21B illustrate molecules and energy is delivered
locally from an energy delivery
device.
-3-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[0032] Fig. 22 illustrates an energy delivery device comprising a
shaft having an energy delivery
body near its distal end, wherein the energy delivery body comprises a
plurality of tines.
[0033] Fig. 23 illustrates an energy delivery device comprising an
energy delivery body having a
basket shape configured for treating target tissue endoluminally.
[0034] Fig. 24 illustrates another embodiment of an energy delivery
device comprising an energy
delivery body having a shape configured for treating target tissue
endoluminally, wherein the energy
delivery body comprises at least two protrusions, each protrusion extending
radially outwardly so as to
contact an inner luminal wall.
[0035] Fig. 25 illustrates another embodiment of an energy delivery
device comprising an energy
delivery body having a shape configured for treating target tissue
endoluminally, wherein the energy
delivery body comprises an expandable member, such as an inflatable balloon,
having an electrode
mounted thereon or incorporated therein.
[0036] Fig. 26 illustrates an embodiment of an energy delivery
device wherein the delivery body has
a finger-tip shape configured to contact an inner lumen wall.
SUMMARY OF THE INVENTION
[0037] Described herein are embodiments of apparatuses, systems and
methods for treating target
tissue in the body. Likewise, the invention relates to the following numbered
clauses:
[0038] 1. A system for treating a target tissue area of a patient
comprising:
an energy delivery device having at least one energy delivery body configured
to be positioned
near the target tissue area within the patient; and
a generator in electrical communication with the at least one energy delivery
body, wherein the
generator includes at least one energy delivery algorithm configured to
provide an electric signal of
pulsed electric field energy deliverable to the at least one energy delivery
body so as to induce
extravasation within the target tissue area.
[0039] 2. A system as in claim 1, wherein the induced
extravasation is sufficient to bias
molecules delivered to the target tissue area toward entry to cells of the
target tissue area.
[0040] 3. A system as in claim 2, wherein the molecules comprise
drugs, chemotherapy drugs,
immunotherapy drugs, and/or monoclonal antibodies.
[0041] 4. A system as in claim 2, wherein the molecules include
auxiliary materials including
polymeric nanoparticles, liposomes, PEGylated liposomes, lipofectamine, cell-
penetrating peptides
(CPC), dimethyl sulfoxide (DMSO), cholesterol, or other materials known to
interact with cell membrane
fluidity and mechanics.
[0042] 5. A system as in any of claims 2-4, wherein the energy
delivery device is configured to
deliver the molecules to the target tissue area of the patient.
-4-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[0043] 6. A system as in any of the above claims, wherein the
extravasation delivers molecules
from vasculature within the target tissue area to interstitial spaces around
cells within the target tissue
area.
[0044] 7. A system as in any of the above claims, further
comprising a controller that is
configured to control delivery of the pulsed electric field energy in response
to at least one component.
[0045] 8. A system as in claim 7, wherein the at least one
component comprises a sensor that
senses a flow rate of molecules being delivered to the patient.
[0046] 9. A system as in claim 7, wherein the at least one
component comprises a sensor that
senses pressure of a syringe pump configured to deliver molecules to the
patient.
[0047] 10. A system as in claim 7, wherein the at least one
component comprises a timer and
wherein the controller causes delivery of the pulsed electric field energy at
a predetermined time after
commencement of delivery of molecules to the target tissue area.
[0048] 11. A system as in any of claims 7-10, wherein the
controller causes delivery of the
pulsed electric field energy throughout delivery of molecules to the target
tissue area.
[0049] 12. A system as in any of claims 7-11, wherein the
controller causes delivery of the
pulsed electric field energy throughout delivery of molecules to the target
tissue area and continues 200-
300% longer than the delivery of molecules.
[0050] 13. A system as in any of claims 7-11, wherein the
controller causes delivery of the
pulsed electric field energy throughout an additional delivery of molecules
that occurs at a time period
after the delivery of molecules.
[0051] 14. A system as in any of the above claims, wherein the
electric signal of pulsed electric
field energy deliverable to the at least one energy delivery body so as to
induce extravasation within the
target tissue area also causes cell death within the target tissue area.
[0052] 15. A system as in claim 14, wherein the signal comprises
at least two packets of biphasic
pulses separated by an inter-packet delay.
[0053] 16. A system as in claim 15, wherein each packet
comprises 10-40 biphasic pulses.
[0054] 17. A system as in claim 16, wherein each of the biphasic
pulses arc separated by a cycle
delay of 1000 s.
[0055] 18. A system as in any of claims 15-17, wherein each
packet has an on-time of 70-100p.
[0056] 19. A system as in any of claims 15-18, wherein the at
least two packets comprises 50-
200 packets.
[0057] 20. A system as in any of claims 15-19, wherein, the
inter-packet delay is in a range of 3
to 6 seconds.
[0058] 21. A system as in any of claims 15-20, wherein the
electric signal has a voltage in a
range of 3000V-6000V.
[0059] 22. A system as in any of claims 15-21, wherein the
signal has a frequency in a range of
100-400kHz.
-5-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[0060] 23. A system as in any of claims 1-13, wherein the
generator further includes at least one
additional energy delivery algorithm configured to provide an additional
electric signal of pulsed electric
field energy deliverable to the at least one energy delivery body so as to
cause cell death within the target
tissue area.
[0061] 24. A system as in claim 23, wherein the electric signal
is comprised of a plurality of
pulses having a pulse width of greater than 5001.ls.
[0062] 25. A system as in claim 24, wherein at least one of the
plurality of pulses is separated by
a delay of 10 s-10 seconds.
[0063] 26. A system as in claim 24, wherein each of the
plurality of pulses is biphasic.
[0064] 27. A system as in claim 26, wherein at least one of the
plurality of pulses is separated by
a delay of 1 s-1 second.
[0065] 28. A system as in any of claims 23-27, wherein the
additional electric signal is
comprised of a plurality of pulses forming a packet, wherein each of the
plurality of pulses has a duration
of 0.5 -200us, and wherein the packet has a cumulative on-time of 1-200us.
[0066] 29. A system as in claim 28, wherein the additional
electric signal comprises 40-100
packets.
100671 30. A system as in any of the above claims, wherein the
target tissue area comprises cells
of a digestive system, including a liver, a pancreas, a stomach, intestines
and/or colon.
[0068] 31. A system as in any of claims 1-29, wherein the target
tissue area comprises cells of a
respiratory system including a lung, an airway, a bronchial passageway, and/or
an alveolar sac.
[0069] 32. A system as in any of claims 1-29, wherein the target
tissue area comprises cells of a
reproductive system including a vagina, a uterus, a cervix, a fallopian tube,
an ovary, a testicle, a penis, an
epididymis, a vas deferens, a urethra, a prostate gland, a seminal vesicle,
and/or a bulbourethral gland.
[0070] 33. A system as in any of the above claims, wherein the
target tissue area comprise at
least a portion of a tumor or an abnormal growth.
[0071] 34. A system as in any of the above claims, wherein the
energy delivery body is
configured to function in a monopolar manner.
[0072] 35. A system for treating a target tissue area of a patient
comprising:
an energy delivery device configured to deliver energy to the target tissue
area and configured to
deliver a plurality of molecules to the target tissue area: and
a generator in electrical communication with the energy delivery device,
wherein the generator
includes at least one energy delivery algorithm configured to provide an
electric signal of pulsed electric
field energy deliverable to the at least one energy delivery body that induces
extravasation within the
target tissue area wherein the extravasation is sufficient to bias molecules
delivered to the target tissue
area toward entry to cells of the target tissue area.
[0073] 36. A system as in claim 35, further comprising a
controller that coordinates delivery of
the pulsed electric field energy and the delivery of the plurality of
molecules.
-6-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[0074] 37. A system as in claim 36, wherein the controller
causes commencement of the delivery
of the pulsed electric field energy at a predetermined time after commencement
of delivery of the
plurality of molecules.
[0075] 38. A system as in any of claims 36-37, wherein the
controller causes simultaneous
delivery of the pulsed electric field energy and delivery of molecules to the
target tissue area throughout a
treatment of the target tissue area.
[0076] 39. A system as in claim 38, wherein the electric signal
of pulsed electric field energy
deliverable to the at least one energy delivery body so as to induce
extravasation within the target tissue
area also causes cell death within the target tissue area, and wherein
treatment of the target tissue area
comprises cell death within at least a portion of the target tissue area.
[0077] 40. A system as in any of claims 36-39, wherein the
controller causes delivery of the
pulsed electric field energy throughout delivery of molecules to the target
tissue area and continues 200-
300% longer than the delivery of molecules.
[0078] 41. A system as in any of claims 36-40, wherein the
controller causes delivery of the
pulsed electric field energy throughout an additional delivery molecules that
occurs at a time period after
the delivery of molecules.
[0079] 42. A system as in any of the above claims, wherein the
electric signal of pulsed electric
field energy deliverable to the at least one energy delivery body so as to
induce extravasation within the
target tissue area also causes cell death within the target tissue area.
[0080] 43. A system as in claim 42, wherein the signal comprises
at least two packets of biphasic
pulses separated by an inter-packet delay.
[0081] 44. A system as in claim 43, wherein each packet
comprises 10-40 biphasic pulses.
[0082] 45. A system as in any of claims 43-44, wherein each of
the biphasic pulses are separated
by a cycle delay of 1000p.
[0083] 46. A system as any of claims 43-45, wherein each packet
has an on-time of 70-100),ts.
[0084] 47. A system as in any of claims 43-46, wherein the at
least two packets comprises 50-
200 packets.
[0085] 48. A system as in any of claims 43-47, wherein, the
inter-packet delay is in a range of 3
to 6 seconds.
[0086] 49. A system as in any of claims 43-48, wherein the
electric signal has a voltage in a
range of 3000V-6000V.
[0087] 50. A system as in any of claims 43-49, wherein the
signal has a frequency in a range of
100-400kHz.
[0088] 51. A system as in claim 35, wherein the electric signal
is comprised of a plurality of
pulses having a pulse width of greater than 500p.s.
[0089] 52. A system as in claim 51, wherein at least one of the
plurality of pulses is separated by
a delay of 101,ts-10 seconds.
-7-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[0090] 53. A system as in claim 51, wherein each of the
plurality of pulses is biphasic.
[0091] 54. A system as in claim 53, wherein at least one of the
plurality of pulses is separated by
a delay of 1us-1 second.
[0092] 55. A system as in claim 35, wherein the generator
further includes at least one additional
energy delivery algorithm configured to provide an additional electric signal
of pulsed electric field
energy deliverable to the at least one energy delivery body so as to cause
cell death within the target
tissue area.
[0093] 56. A system as in claim 55, wherein the additional
electric signal is comprised of a
plurality of pulses forming a packet, wherein each of the plurality of pulses
has a duration of 0.5 -200us,
and wherein the packet has a cumulative on-time of 1-200us.
[0094] 57. A system as in any of claims 55-56, wherein the
additional electric signal comprises
40-100 packets.
[0095] 58. A system as in any of claims 35-57, wherein the
target tissue area comprises cells of a
digestive system, including a liver, a pancreas, a stomach, intestines and/or
colon.
[0096] 59. A system as in any of claims 35-57, wherein the
target tissue area comprises cells of a
respiratory system including a lung, an airway, a bronchial passageway, and/or
an alveolar sac.
100971 60. A system as in any of claims 35-57, wherein the
target tissue area comprises cells of a
reproductive system including a vagina, a uterus, a cervix, a fallopian tube,
an ovary, a testicle, a penis, an
epididymis, a vas deferens, a urethra, a prostate gland, a seminal vesicle,
and/or a bulbourethral gland.
[0098] 61. A system as in any of claims 35-60, wherein the
target tissue area comprise at least a
portion of a tumor or an abnormal growth.
[0099] 62. A system as in any of claims 35-61, wherein the
energy delivery body is configured
to function in a monopolar manner.
[00100] 63. A system for killing cells within a target tissue
area of a patient comprising:
an energy delivery device having at least one energy delivery body configured
to be positioned
near the target tissue area within the patient; and
a generator in electrical communication with the at least one energy delivery
body, wherein the generator
includes at least one energy delivery algorithm configured to provide an
electric signal of pulsed electric
field energy deliverable to the at least one energy delivery body so as to
induce extravasation within the
target tissue area and kill cells within the target tissue area.
[00101] 64. A system as in claim 63, wherein the induced
extravasation is sufficient to bias
molecules delivered to the target tissue area toward entry to cells of the
target tissue area.
[00102] 65. A system as in claim 64, wherein the molecules
comprise drugs, chemotherapy drugs,
immunotherapy drugs, and/or monoclonal antibodies and wherein at least some of
the cells are killed by
entry of the molecules.
[00103] 66. A system as in any of claims 63-65, wherein the
energy delivery device includes at
least one pressure sensor.
-8-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00104] 67. A system as in claim 66, wherein the at least one
pressure sensor is configured to
monitor effects of the extravasation and provide sensor feedback data.
[001051 68. A system as in claim 67, wherein the system includes
a mechanism to provide the
sensor feedback data or information based on the sensor feedback data to a
user.
[001061 69. A system as in claim 68, wherein the generator
includes a processor configured to
modify the at least one energy delivery algorithm or switch to a different
energy delivery algorithm based
on the sensor feedback data so as to transmit energy which adjusts inducement
of extravasation.
[00107] 70. A system as in any of claims 63-65, wherein the
system includes at least one sensor.
[00108] 71. A system as in claim 70, wherein the at least one
sensor comprises a sensor that
monitors pressure, temperature, impedance, resistance, capacitance,
conductivity, pH, optical properties,
coherence, echogenicity, fluorescence, electrical permittivity, light
permittivity, and/or conductance.
[00109] 72. A method for conditioning a target tissue area within
a patient comprising:
positioning at least one electrode near the target tissue area; and
delivering pulsed electric field energy through the at least one electrode to
the target tissue area, wherein
the pulsed electric field energy is configured to induce extravasation causing
edema within the target
tissue area.
[001101 73. A method as in claim 72, further comprising
delivering a plurality of molecules to the
patient so that the induced extravasation increases a concentration of
molecules from the plurality of
molecules within the target tissue area.
[001111 74. A method as in claim 73, wherein the pulsed electric
field energy is configured to
treat the target tissue area and wherein delivering the plurality of molecules
occurs throughout delivery of
the pulsed electric field energy to treat the target tissue area.
[00112] 75. A method as in claim 74, wherein treating the target
tissue area comprises killing
cells within the target tissue area.
[001131 76. A method as in claim 75, wherein the target tissue
area comprises a tumor and
wherein killing cells within the target tissue area comprises substantially
destroying the tumor.
[00114] 77. A method as in claim 73, wherein the pulsed electric
field energy is configured to
treat the target tissue area and wherein delivering the plurality of molecules
occurs only during a first
portion of delivery of the pulsed electric field energy to treat the target
tissue area.
[001151 78. A method as in claim 77, wherein the first portion
comprises 25-33% of delivery of
the pulsed electric field energy to trat the target tissue area.
[001161 79. A method as in claim 73, wherein the pulsed electric
field energy is configured to
treat the target tissue area and wherein delivering the plurality of molecules
occurs only during a first
portion of delivery of the pulsed electric field energy to treat the target
tissue area and a last portion of
delivery of the pulsed electric field energy to treat the target tissue area.
-9-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00117] 80. A method as in claim 79, wherein the first portion
comprises 25% of delivery of the
pulsed electric field energy to treat the target tissue area and the second
portion comprises 25% of
delivery of the pulsed electric field energy to treat the target tissue area.
[00118] 81. A method as in claim 72, wherein the target tissue
area is near vasculature of the
patient and wherein the energy is configured to induce extravasation of fluid
from the vasculature causing
edema within the target tissue area.
[00119] 82. A method as in claim 81, further comprising
delivering a plurality of molecules to the
vasculature and wherein the energy is configured to induce extravasation of a
portion of the plurality of
molecules with the fluid.
[001201 83. A method as in claim 72, wherein the target tissue
area is near lymphatics of the
patient and wherein energy is configured to induce extravasation of fluid from
the lymphatics causing
edema within the target tissue area.
[001211 84. A method as in claim 72, wherein the target tissue
area comprises cells of a digestive
system, including a liver, a pancreas, a stomach, intestines and/or colon.
[00122] 85. A method as in claim 72, wherein the target tissue
area comprises cells of a
respiratory system including a lung, an airway, a bronchial passageway, and/or
an alveolar sac.
[001231 86. A method as in claim 72, wherein the target tissue
area comprises cells of a
reproductive system including a vagina, a uterus, a cervix, a fallopian tube,
an ovary, a testicle, a penis, an
epididymis, a vas deferens, a urethra, a prostate gland, a seminal vesicle,
and/or a bulbourethral gland.
[001241 87. A method as in claim 72, wherein the target tissue
area comprises at least a portion of
a tumor or an abnormal growth.
[00125] 88. A method as in claim 72, further comprising
delivering a second energy through the
at least one electrode to the target tissue area, wherein the second energy is
configured to ablate the target
tissue area.
[001261 89. A method as in claim 88, wherein the second energy
comprises pulsed electric field
ablation energy.
[00127] 90. A method as in claim 88, wherein the second energy
comprises microwave ablation
energy, radiofrequency ablation energy, cryoablation energy, and/or high
intensity focused ultrasound
(HIFU) energy.
[001281 91. A method as in claim 72, wherein the target tissue
area is near vasculature of the
patient and wherein the energy is configured to induce extravasation of fluid
from the vasculature causing
edema within the target tissue area.
[00129] 92. A method for increasing a concentration of a
plurality of molecules near target cells
of a patient comprising:
introducing the plurality of molecules to the patient;
positioning at least one electrode within the patient; and
-10-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
delivering pulsed electric field energy via the at least one electrode so as
to induce cxtravasation
in a manner that increases the concentration of the plurality of molecules
amongst the target cells.
[00130] These and other embodiments arc described in further
detail in the following description
related to the appended drawing figures.
INCORPORATION BY REFERENCE
[00131] All publications, patents, and patent applications
mentioned in this specification are
herein incorporated by reference to the same extent as if each individual
publication, patent, or patent
application was specifically and individually indicated to be incorporated by
reference.
DETAILED DESCRIPTION
[00132] Devices, systems and methods are provided for improving treatment of
target tissue within a
body of a patient, particularly improving treatment of tumors within a body of
a patient. Tumors arc
typically treated by a variety of methods, including chemotherapy or the
delivery of other molecules to
the tumor site, either systemically or locally. The devices, systems and
methods described herein provide
improved outcomes, particularly as related to improvement in the uptake of
molecules to the cells and
ultimately increased cell death and tumor elimination.
[00133] Such devices, systems and methods involve the delivery of energy, such
as pulsed electric
field energy (PEF) or other suitable energy types, to induce extravasation of
fluids and optionally
molecules to the target tissue area. In some instances, the energy is the same
as the treatment energy and
in other instances the energy is different, such as a particular conditioning
energy. When the energy is the
same, both may be PEF energy and when the energy is different, the
conditioning energy may be PEF
energy and the treatment energy may be PEF energy having a different waveform
or treatment parameters
or the energy may be of a different type, such as microwave ablation,
radiofrequency ablation,
cryoablation, and/or high intensity focused ultrasound (HIFU).
[00134] In some embodiments, PEF energy is used to treat damaged, diseased,
abnormal, obstructive,
cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant
tumor, a cyst, or an area of
diseased tissue, etc). The energy is delivered in a manner so as to be non-
thermal (i.e. below a threshold
for causing thermal ablation). Consequently, when extracellular matrices are
present, the extracellular
matrices are preserved, and the targeted tissue maintains its structural
architecture including blood vessels
and lymphatics. Thus, sensitive structures, such as biological lumens, blood
vessels, nerves, etc, are able
to be preserved which are critical to maintaining the integrity and
functionality of the tissue. This
provides a number of benefits. To begin, this allows for the treatment of
tissues that are often considered
untreatable by conventional methods. Target tissues that are near sensitive
structures are typically
unresectable by surgical methods due to the inability to thoroughly and
effectively surgically separate the
tissue from the sensitive structures. Likewise, many conventional non-surgical
therapies are
contraindicated due to the potential for damage to the sensitive structures by
the therapy or because the
-1 1 -
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
therapies arc deemed ineffective due to the proximity of the sensitive
structures. In addition, the ability to
treat tissue near sensitive structures also provides a more comprehensive
treatment in that malignant
margins are not left near sensitive structures. Once tissue is treated, the
survival of the structural
architecture also allows for the natural influx of biological elements, such
as components of the immune
system, or for the introduction of various agents to further the therapeutic
treatment.
[00135] It may be appreciated that the energy that induces extravasation is
typically referred to as
conditioning energy herein throughout, however, it may be appreciated that in
some instances the
conditioning energy is also the treatment energy. Extravasation is typically
from nearby vasculature,
lymphatics, or other tissue which receives the energy. In some instances, the
extravasation is edema or
edema-like wherein capillaries leak fluid into the surrounding tissue. Edema
occurs when an atypical
volume of fluid accumulates in the tissues, either within cells (cellular
edema) or within the collagen-
mucopolysaccharide matrix distributed in the interstitial spaces (interstitial
edema). The device, systems
and methods described herein focus on swelling of the extracellular matrix or
interstitial edema.
Naturally occurring interstitial edema may occur as a result of aberrant
changes in the pressures
(hydrostatic and oncotic) acting across the microvascular walls, alterations
in the molecular structures that
comprise the barrier to fluid and solute flux in the endothelial wall that are
manifest as changes in
hydraulic conductivity and the osmotic reflection coefficient for plasma
proteins, or alterations in the
lymphatic outflow system. However, the devices, systems and methods described
herein induce the
edema or extravasation by the delivery of specialized energy. In some
instances, the extravasation of
fluid from the blood vessels carries molecules that are delivered
intravenously into the target tissue area.
In other instances, molecules are delivered regionally or locally, such as by
injection, and extravasation of
fluid from the blood vessels concentrates the molecules within the area of
extravasation. And in still
other instances, extravasation is utilized alone without the delivery of
molecules, such as to condition the
target tissue area for treatment.
[00136] The induced extravasation has a variety of beneficial effects for the
treatment. Example
improvements to the treatment therapy include, but are not limited to,
conditioning the target tissue,
increasing the availability of molecules, increasing the uniformity of the
availability of molecules,
increasing access to naturally restricted target tissues, creating larger
treatment areas, and reducing
potential undesired side effects, to name a few. Each of these will be
described in more detail
hereinbelow.
1. Overview
A. Extravasation and Treatment Methodology
[00137] The devices, systems and methods described herein are suitable for
treating a variety of
different types of target tissue in various anatomical locations. In some
embodiments, the target tissue is
abnormal tissue. Abnormal tissue can take a variety of different forms, such
as damaged, diseased,
obstructive, cancerous or undesired tissue. In some instances, the abnormal
tissue is a tumor, such as a
benign tumor or a malignant tumor, a cyst, or an area of diseased tissue. One
of the most troublesome
-12-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
types of abnormal tissue is related to cancer. For example purposes, an
embodiment related to treating a
cancerous tumor in the lung anatomy is provided. However, it may be
appreciated that other types of
tissue may be treated and other locations of the body may be treated with the
same devices, systems and
methodology. For example, any tissues located sufficiently close to
capillaries may be treated so as to
receive the extravasation. Likewise, any tissues located sufficiently near a
lumen for endoluminal access,
such as near a blood vessel, an esophagus, a stomach, a pancreatic duct, a
biliary duct, a small intestine, a
large intestine, a colon, a rectum, a bladder, a urethra, a urinary collecting
duct, a uterus, a vagina, a
fallopian tube, a ureter, a renal tubule, a spinal canal, a spinal cord, an
airway, a nasal cavity, a mouth, a
heart chamber, a heart lumen, a kidney lumen, and an organ lumen, may be
treated so as to benefit from
minimally invasive access. However, it may be appreciated that tissues that
are not sufficiently near a
lumen may be accessed by other methods, such as percutaneously or surgically.
[00138] Fig. 1 illustrates a tumor T within a lung L of a patient P. The tumor
T is located within a
right upper lobe of the lung L. The lung anatomy is highly vascularized, as
illustrated in Fig. 2. Fig. 2
schematically illustrates the pulmonary artery distribution throughout the
lungs L. Thus, many locations
within the lung L are located near a blood vessel. Fig. 3 illustrates an
endoluminal approach to the tumor
T. Here, a bronchoscope 50 is advanced through the trachea and the right
mainstem bronchus toward the
tumor T. Fig. 4 illustrates the distal end of the bronchoscope 50 advanced
through the lung passageways
so as to reach the tumor T. A catheter or instrument or energy delivery device
102 is then advanced from
the distal end of the bronchoscope 50 toward the tumor T. In this instance,
the energy delivery device
102 has an elongate shaft 106 with at least one energy delivery body 108 near
its distal end and a handle
110 at its proximal end. The energy delivery device 102 is connectable to a
generator 104 as part of a
treatment system 100, as will be described in more detail in later sections.
Fig. 4 illustrates the energy
delivery device 102 emerging from the bronchoscope 50, toward the wall of the
lung passageway. In this
embodiment, the energy delivery body 108 has the form of a needle which is
able to pierce the wall of the
lung passageway and the tumor T.
[00139] Figs. 5A-5C illustrate a portion of the lung L of Fig. 1 near the
tumor T during stages of the
extravasation procedure. In this embodiment, the energy delivery device 102
comprises an elongate shaft
106 and an energy delivery body 108 disposed near the distal end of the
elongate shaft 106. As
mentioned, in this embodiment, the energy delivery body 108 is comprised of a
single electrode and the
distal tip 103 is configured to penetrate the tumor T. It may be appreciated
that in other embodiments the
energy delivery body 108 has an atraumatic tip and is delivered via a separate
instrument that is able to
penetrate tissue. As illustrated in Fig. 5A, the energy delivery body 108 is
positioned within the tumor T
near blood vessels By, such as capillaries. In this embodiment, molecules 110
are delivered to the target
tissue area (e.g. tumor T) through the blood vessels By, such as by
intravenous (IV) administration. Such
molecules 110 are particular to the treatment provided. In this example, the
molecules 110 comprise
chemotherapeutic agents to enhance the treatment effect on the tumor T. Such
enhancement may increase
the efficacy of therapeutic treatment or improve the ability to treat larger
treatment areas, particularly
-13 -
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
with reduced possibility of thermal damage. It may be appreciated that the
examples provided based on a
cancerous tumor are for illustration purposes and the principles described
herein may be applied to the
treatment of other undesired or diseased tissues. Likewise, other drugs,
agents or molecules (e.g. DNA
plasmids, RNAs (e.g. messenger RNA (mRNA), small interfering RNA (siRNA),
micro RNA),
oligonucleotides, antisense oligonucleotides (ASO), proteins and/or materials
which invoke genetic or
epigenetic changes in the cellular behavior) may be delivered in the
therapeutic treatment of the target
tissue and is not limited to chemotherapeutic agents. Such drugs, agents and
molecules will be
collectively considered molecules. Example molecules will be further described
in later sections. It may
be appreciated that in other embodiments, the molecules 110 are delivered by
the energy delivery device
102 itself or by a separate device, such as by catheter or needle injection.
[001401 Fig. SA shows that only a few molecules 110 have entered the target
tissue area but a
significant quantity remains within the blood vessels By. At least one dose of
energy is then delivered to
the target tissue area from the energy delivery body 108 as indicated by wavy
lines 113, as illustrated in
Fig. 5B. Typically, the energy comprises a specialized form of PEF energy,
however it may be
appreciated that other types of specialized energy may be used to cause the
desired extravasation. In this
embodiment, specialized PEF energy reversibly disrupts the fluid-barrier
functional integrity of the
endothelial cells within the blood vessels By, such as by affecting the
hydraulic conductivity and osmotic
reflection coefficient for plasma proteins. This disruption causes the barrier
to be less able to restrict the
movement of fluid and macromolecules from the blood to the interstitium of the
surrounding tissue. This
causes extravasation and a flooding of the target tissue area with fluid and
solutes, including molecules
110 from the blood vessels By, as illustrated in Fig. SC. The PEF energy
typically disrupts the capillaries
while causing minimal destruction of cells in the targeted area. However, it
may be appreciated that such
disruption may be utilized in conjunction with treatments intended to destroy
cells, such as in the
treatment of cancer or abnormal tissue.
[001411 This process of extravasation may occur over a period of time, such as
5 seconds, or 30
seconds to 15 minutes, however extravasation typically occurs between 30
seconds to 30 minutes.
Therefore, delivery of the molecules 110 may be timed in various ways during
the extravasation process
so as to maximize its benefits. In some instances, it is desirable to begin
delivery of the molecules 110 to
the vasculature prior to delivery of the PEF energy to ensure maximum
concentration and availability of
the molecules 110 in the bloodstream. In some instances, it is desirable to
continuously deliver molecules
110 throughout the delivery of the PEF energy. And, in other instances it is
desirable to deliver
molecules only at various timepoints or over various time periods during the
delivery of the PEF energy.
The time period of extravasation and edema generation may vary in length
depending on a variety of
factors including the targeted organ, parameters used, and specific objectives
of the therapy. For instance,
molecules 110 that are not provided at a high systemic concentration may
involve maximal extravasation
effects prior to and/or during the therapeutic procedure. Likewise, molecules
110 that arc heavily
bioavailable may involve lesser extravasation effects prior to and/or during
the therapeutic procedure. It
-14-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
is typically desired that the blood vessels BV be at their leakiest during the
period that the concentration
of the molecules 110 passing through these blood vessels BV are at the
highest, thus providing the
greatest extravasation of molecules 110 into the targeted tissue area
interstitial environment.
[00142] The induced extravasation provides a variety of advantages. Example
advantages include but
are not limited to creating a larger treatment area, conditioning the
treatment area to be more receptive to
therapeutic treatment, increasing the availability of molecules, increasing
the uniformity of the
availability of molecules, increasing delivery of molecules to locations that
are naturally restricted, such
as across the blood brain barrier, and reducing the likelihood of potential
side effects of the treatment.
Each of these will be described in more detail in later sections.
[001431 In this embodiment, the molecules 110 are intended to be taken up by
the cells of the target
treatment area. In some embodiments, the induced extravasation alone is
sufficient to increase the uptake
of the molecules 110 by the cells of the target tissue area. In other
embodiments, uptake of the molecules
110 is further facilitated with the delivery of therapeutic energy. In some
embodiments, the therapeutic
energy is comprised of PEF energy having a different waveform than the pre-
conditioning PEF energy. It
may be appreciated that in some embodiments, the therapeutic PEF energy is
delivered with the same
energy delivery body 108 positioned within the target tissue area. In other
embodiments, a different
device is used to deliver the therapeutic energy.
[001441 It may be appreciated that in other embodiments the molecules 110 are
not intended to be
taken up by the cells to evoke an effect. For instance, molecules 110
comprising ligands, eytokines,
tumor necrosis factor (TNF) or vascular endothelial growth factor (VEGF), etc.
may be delivered to the
area as part of a therapeutic treatment that does not involve uptake of these
molecules 110. In such
instances, the extravasation provides a variety of benefits, such as increased
availability and uniformity,
regardless of increased uptake.
[001451 In this embodiment, the extravasation process if followed by treatment
of the tumor T. Fig. 6
illustrates the energy delivery body 108 inserted in the tumor T. In this
embodiment, specialized pulsed
electric field (PEF) energy is delivered to target tissue areas via the energy
delivery body 108. Typically,
the treatment PEF energy differs from the conditioning PEF energy. However, it
may be appreciated that
in some instances the two energies have the same waveform or other
similarities. Such therapies cause
the undesired cells to be destroyed, eliminated, killed, removed, etc., while
maintaining non-cellular
elements, such as collagen, elastin, and matrix proteins. Therefore, the
integrity and mechanical
properties of the tissue, and any nearby himinal stnietures, are maintained
while abnormal or diseased
cells and tissues are sufficiently eliminated. It may be appreciated that
other forms of energy or other
treatment modalities may be used to treat the target tissue, such as other
focal therapies including
microwave ablation, radiofrequency ablation, cryoablation, and/or high
intensity focused ultrasound
(HIFU).
[001461 In this embodiment, as illustrated in Fig. 6, the PEF energy typically
creates various zones of
treatment extending radially outwardly from the energy delivery body 108. As
shown, a zone closest to
-15-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
the energy delivery body 108 (i.e. the central zone 107) endures immediate
cell death, such as via
necrosis. In this embodiment, a zone surrounding the central zone (i.e. the
peripheral zone 109) endures
delayed cell death, such as via programmed cell death. Fig. 7 illustrates that
what was once a tumor T is
now a debris field DF that extends outwards to the peripheral margin 111. The
debris field DF is then
cleared by the immune system of the patient P, as illustrated in Figs. 8A-8B.
Fig. 8A illustrates dendritic
cells DC and other immune cells sweeping out (as indicated by arrows) of the
adjacent intact lung tissue
LT and into the debris field DF. The dendritic cells DC internalize the
remaining cell fragments,
antigens, and damage-associated molecular patterns (DAMPs). DAMPs are
molecules released upon
cellular stress or tissue injury and are regarded as endogenous danger signals
because they induce potent
inflammatory responses by activating the innate immune system during non-
infectious inflammation.
Fig. 8B illustrates the dendritic cells DC and other immune cells moving out
(as indicated by arrows) of
the debris field DF and back into the surrounding lung tissue LT. The
dendritic cells DC and other
immune cells enter afferent lymphatic ducts LD, as illustrated in Fig. 9,
travel towards the nearest tumor
draining lymph node and on to a network of lymph nodes LN. Fig. 10 illustrates
the original tumor T site
which is now a debris field DF with nearby lymph nodes LN. This causes
activated T-cells to flow from
the lymph nodes LN (indicated by the arrow) to the heart H which then
distributes the T-cells throughout
the body, including the upper right lobe of the lung L where the original
tumor T resided. The T-cells
then infiltrate the debris field DF via the vasculature. The residual tumor
cells T arc recognized by the
antigens on their cell surface and the T-cells release perforin and cytotoxins
to kill them. Any residual
tumor cells are killed by perforin and granzymes which are released from the T-
cells. In some
embodiments, check-point inhibitors are provided which also support this
process. Such cell death
repeats the cycle through the lymph nodes LN, activating more T-cells. This
may be repeated several
times.
[00147] In addition, the T-cells may encounter distant metastases. Fig. 11
illustrates these steps: (1)
dendritic cells DC and other immune cells traveling through lymphatic ducts LD
to lymph nodes LN, (2)
activated T-cells traveling to the heart H, (3) activated T-cells traveling to
remote locations in the body.
Fig. 12 illustrates the activated T-cells of step (3) traveling to metastatic
tumors Ti, T2 in the liver LR.
The same process then ensues in relation to the metastatic tumors Ti, T2,
activating more T-cells. This
assists in eliminating cancerous tumors throughout the patient's body.
[00148] It may be appreciated that in some instances the lymph nodes
themselves are the target tissue,
such as lymph nodes which contain cancer cells, such as metastatic cancer
cells. In such instances, the
target lymph tissue would be treated in the same or similar manner as the
tumor T described herein. This
would also release activated T-cells which would travel throughout the body.
B. Extravasation Advantages
[00149] The induced extravasation may have a variety of effects that are
beneficial to the therapeutic
treatment provided to the target tissue area. Example improvements to the
treatment therapy include, but
-16-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
arc not limited to, conditioning the target tissue, increasing the
availability of molecules, increasing the
uniformity of the availability of molecules, increasing access to naturally
restricted target tissues, creating
larger treatment areas, and reducing potential undesired side effects, to name
a few. In instances where
the target tissue area is a cancerous tumor, the therapeutic treatment may
include delivery of
chemotherapeutic agents and/or the delivery of focal therapies, such as
microwave ablation,
radiofrequency ablation, cryoablation, high intensity focused ultrasound
(HIFU), and pulsed electric field
ablation therapies configured to destroy cells. Thus, in these instances, the
induced extravasation may be
considered part of a pre-conditioning or conditioning regime and would be
utilized in conjunction with
the therapeutic treatment (e.g. chemotherapy, focal therapy, combination of
chemotherapy and focal
therapy, etc.) to enhance the treatment effect. It may be appreciated that the
examples provided based on
a cancerous tumor are for illustration purposes and the principles described
herein may be applied to the
treatment of other undesired or diseased tissues. Likewise, other drugs,
agents or molecules (e.g. DNA
plasmids, RNAs (e.g. messenger RNA (mRNA), small interfering RNA (siRNA),
micro RNA),
oligonucleotides, antisense oligonucleotides (ASO), proteins and/or materials
which invoke genetic or
epigenetic changcs in the cellular behavior) may be delivered in the
therapeutic treatment of the target
tissue and is not limited to chemotherapeutic agents. Such drugs, agents and
molecules will be
collectively considered molecules.
[00150] In some embodiments, the induced extravasation enables the generation
of a larger treatment
area by acting as a virtual or fluid electrode. The extravasating fluid or
edema is comprised of naturally
conductive material, and therefore when it gathers within the target treatment
area and is in contact with
the energy delivery body 108 it extends the range of the energy delivery body
108 through the conductive
edema fluid. This may increase the size of an ablative lesion, such as width,
depth, volume, etc. This
may also increase the regional selectivity of the PEF ablation.
[00151] In some embodiments, the induced edema alters the electrical
properties of the cellular
microenvironment of the target tissue area. This may improve the efficiency
and conduction of the
therapeutic PEF energy through the target tissue area. In particular, the
induced edema may reduce the
electric field threshold for the cells to succumb to cell death, such as
through loss of homeostasis or
energy depletion. This may allow the therapeutic PEF energy protocol to use
reduced intensity, reducing
any potential thermal effects, easing generator demands, in addition to
expanding the treatment area.
Thus, in some embodiments, the induced edema normalizes the target tissue area
before therapeutic
treatment (such as to create a stable impedance environment). The target
tissue area is typically a
heterogenous environment on a microscopic scale, however the introduction of
conductive fluid creates a
more homogenous environment. The high conductivity fluids flow through low
conductivity vessels with
connective tissue, at times with no-conductivity air sacs, and other
structures of widely dispersed
impedances at the microscale. The more homogenous environment behaves more
consistently throughout
the tissue area in accordance with the new bulk-tissue conductivity. This may
be beneficial when
-17-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
providing focal therapy alone or when providing focal therapy in combination
with delivery of molecules
comprising a drug or agent.
[00152] In some embodiments, the induced edema increases thc local
concentration of molecules 110
in the target treatment area, increasing availability of the molecules 110.
When the molecules 110 are
delivered via the vasculature, the extravasation of the molecules 110 from the
vasculature increases the
local concentration in the target treatment area. Likewise, when the molecules
110 are provided by other
methods, the edema effect (e.g. increased interstitial pressure) also
increases the availability of the
molecules 110. It may be appreciated that due to the inability of the target
tissue to readily expand its
interstitial volume, relatively small increments in transcapillary fluid
filtration induce large increases in
interstitial fluid pressure. This creates a pressure gradient, biasing the
molecules 110 toward entry to the
target tissue cells. Similarly, concentration gradients which form also bias
the molecules 110 toward
entry to the target tissue cells.
[00153] In some instances, the induced extravasation creates an improved (e.g.
more uniform)
distribution of the molecules 110 throughout the target treatment area. In
some instances, the induced
edema provides a conduit to increase the distribution rate and final volume
distribution of targeted
materials that enter the interstitial space, such as via extravasation or from
direct injection of the
molecules 110 into the targeted region. As mentioned previously, in some
embodiments, the induced
edema traps the molecules in the target tissue area so that the molecules are
at least temporarily resisted
from diluting back into the blood or lymphatics. Ultimately, the edema is
drained naturally along the
lymphatics. When the edema contains molecules, the excess molecules are then
drained through the
lymphatics as well. In cases such as cancer, where cancer cells migrate along
the lymphatics, the
molecules will be brought to the same lymph nodes to which migratory cancer
cells may arrive,
potentially heading off metastasis.
[00154] In some embodiments, the induced extravasation increases access to
naturally restricted target
tissues. For example, the induced extravasation may allow delivery of
materials across cellular-based
tissue layers that would otherwise block passage of this material from
reaching a targeted population of
cells. For example, molecules 110 delivered to the vitreous humor of the eye
are typically unable to reach
the subretinal space, particularly the retinal pigment epithelium (RPE) and
photoreceptor cells (PR). This
is due to the ganglia and bipolar cells, positioned between the vitreous and
the underlying RPE and PRs,
which are very tightly connected. Consequently, various molecules 110,
particularly large molecules, are
unable to diffuse through these restrictive layers. Delivery of conditioning
energy as described herein to
adjacent to the surface of the retina, either deep in the intravitreal space
or within a surgically produced
subretinal bleb, induces extravasation of fluid from the retinal vasculature.
The inner retina receives its
blood supply from the retinal vasculature which is connected to the central
retinal artery. At the optic
disc, the central retinal artery bifurcates into several branches that provide
the blood supply of the entire
inner retina. The venous part of the retinal circulation is arranged in a
similar way. The central retinal
vein leaves the eye through the optic disc and drains blood into the cavernous
sinus. The diameter of the
-18-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
central retinal artery before it enters the eye as well as the diameters of
the branch arteries is typically
below 200 mm. Hence, these vessels are functionally arterioles, and the venous
vessels are functionally
venules. In some embodiments, extravasation of fluid from the arterioles,
capillaries, suprachoroidal
space, and other regions that may carry molecules 110 accumulates in the
suprachoroidal space or retinal
spaces, among other regions of the eye anatomy that enable diffusion amongst
the various retinal cell
layers. These retinal cell layers may include those targeted in interventional
PEF treatments for
macromolecule uptake, including genetic transfection. Additional fluid in
these environments provides a
superior conduit for diffusion and dispersion of molecules injected
suprachoroidally, vascularly,
intravitreally, or otherwise, amongst the retinal cell layers, including the
ganglia and bipolar cells,
allowing increased transmission of molecules 110 from the vitreous to the
subretinal space.
[001551 In another example, molecules 110 delivered to the vasculature are
often unable to reach
portions of the brain due to the blood-brain barrier. The blood vessels that
vascularize the central nervous
system (CNS) possess unique properties, termed the blood-brain barrier (BBB),
which allow these vessels
to tightly regulate the movement of ions, molecules, and cells between the
blood and the brain. This
precise control of CNS homeostasis allows for proper neuronal function and
also protects the neural tissue
from toxins and pathogens. The physiological barrier is coordinated by a
series of physical, transport, and
metabolic properties possessed by the endothelial cells (ECs) that form the
walls of the blood vessels, and
these properties are regulated by interactions with different vascular,
immune, and neural cells. However,
delivery of conditioning energy as described herein disrupts the blood-brain
barrier so as to allow the
molecules 110 to pass through to deeper cells in the brain. Thus, the PEF
energy may be utilized to
disrupt the BBB, disrupt the BBB with the inclusion of molecules 110 to act as
an adjuvant (e.g. calcium,
chemotherapy, immunostimulants, charge-modulating materials, etc), or disrupt
the BBB with molecules
110 to transfect into cells (e.g. chemotherapy or genetic material including
RNAs, DNA, plasmids, oligos,
etc), to name a few.
[00156] It may be appreciated that in other embodiments, the molecules 110 are
delivered via the
cerebral spinal fluid rather than via the vasculature. Such access may be
achieved by spinal tap. This may
permit direct access of the molecules 110 into the regions of the central
nervous system, such as the
ventricles of the brain. The PEFs may then be used to encourage regional edema
to promote the
distribution and diffusion of the molecules 110 into regions beyond the
ventricles. It may be appreciated
that, in a variety of clinical applications, edema may be used to promote
migration and distribution of
molecules 110 regardless of how the molecules 110 were initially delivered.
Thus, the induced
extravasation of fluid may be used as a secondary delivery mechanism that
assists the primary delivery.
[00157] In yet another example, molecules 110 delivered to blood vessels
throughout the body are
often unable to reach the innermost layers of the lumen walls, such as for
treating the blood vessels
themselves. In some instances, passage of molecules 110 through the
endothelial lining of blood vessels
is challenging. Such passage is typically desired to deliver drugs and other
agents to the smooth muscle
layer and beyond. This may be desired in the prevention of restenosis when
treating occluded blood
-19-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
vessels. In some embodiments, conditioning energy is transmitted to the lumen
wall causing
extravasation of the molecules 110 from the lumen through one or more layers
of the lumen wall.
[00158] In some embodiments, the induced extravasation reduces the likelihood
of secondary effects
from the treatment devices, such as potential arcing and/or thermal effects.
This occurs due to the thermal
sink effects of fluid in a target environment, as well as the nature of most
edematous fluids described
herein being conductive. Thus, in regions where the target electrode may not
have ideal electrical contact
at the tissue-electrode interface (either weak contact, or only partial
contact with the remainder contacting
air or other low-conductivity tissues), the fluid may serve as an electrical
interface to deliver the PEF
energy from the electrode into the surrounding tissue.
[00159] For example, in some instances, an electrode placed in aerated lung
parenchymal tissue will
have sporadic electrical contact with tissue, resulting in very high
electrical currents at the sites of tissue
contact. This results in inefficient PEF energy distribution into the tissue
which may cause thermal
effects, such as carbonization and caramelization of tissue, and may cause
electrical arcing from the
electrode to the tissue. However, after delivering therapeutic or
subtherapeutic PEF energy into the tissue,
the edematous fluid will locally fill the aerated alveolar regions,
particularly those in closest proximity to
the electrode. This fluid will then distribute the PEF energy more evenly
throughout the tissue. This
allows the delivery of stronger PEF treatment protocol waveforms without the
potential of causing arcing,
burning, or other adverse collateral effects.
[00160] In addition to spreading the energy more efficiently, edematous
filling within a region to
improve electrical continuity at the tissue-electrode interface can also
encourage a farther dispersion of
the energy before experiencing much voltage drop, essentially expanding the
effective surface area of the
electrode via a "virtual electrode" effect. This reduces the intensity of the
energy needed to deliver the
same treatment effects. This in turn eases generator demands.
[00161] It may be appreciated that in some embodiments, the conditioning
energy increases the
cellular resistance of the target tissue area to eventual cell death. This may
be desired when the treatment
involves procedures such as gene transfection rather than ablation. In such
instances, uptake of genetic
material by the cells is desired rather than elimination or destruction of the
cells. In such instances, the
target treatment area receives the conditioning energy causing extravasation
of fluid into the area. It is
known that cells experiencing sub-lethal stresses will generate reparative and
preventative responses to
stress, in essence developing resistance to subsequent stresses of a similar
or different nature,
strengthening their resilience For example, in some embodiments, the
conditioning energy causes heat
shock proteins (HSPs) to be released. HSPs are a family of proteins that are
produced by cells in
response to exposure to stressful conditions, such as conditioning energy as
described herein. Although
HSPs were initially described in relation to heat shock, HSPs are now known to
also be expressed during
other stresses including exposure to cold, UV light and during wound healing
or tissue remodeling. Many
members of this group perform chaperone functions by stabilizing new proteins
to ensure correct folding
or by helping to refold proteins that were damaged by the cell stress. This
increase in expression is
-20-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
transcriptionally regulated. Thc dramatic uprcgulation of thc heat shock
proteins is a kcy part of the hcat
shock response and is induced primarily by heat shock factor (HSF).
[00162] In some embodiments, pre-warming of the tissue or cells (prior to the
delivery of the
molecules 110) may start expression of heat-shock proteins, which play a role
in cell injury, repair and
survival. In such embodiments, a warm solution, such as warm saline, may be
injected to the treatment
site wherein the molecules 110 are delivered after a wait period along with
the delivery of energy. The
wait period may be minutes, hours or days after the delivery of the warming
solution. In some
embodiments, the wait period is 5-30 min, 1-2 hours or 1-2 days.
[00163] In other embodiments, the tissue or cells are warmed with the use of
the energy delivery body
108. In such embodiments, the energy is delivered at a controlled rate to
maintain local temperature
within a specific range, such as between 40-50C for a treatment of less than
10 minutes. It may be
appreciated that in some embodiments, heat-shock proteins are triggered around
approximately 41C.
Thus, sub-lethal pulsed electric field delivery may be used to encourage
upregulation of heat-shock
proteins and other damage-repair preparation prior to the stronger treatment
pulsed electric fields. This
encourages cell resilience to injury from the pulsed electric fields and
improves the ability to transfer
molecules to a meaningful number of cells without undesired excessive cell
death. Thus, in one
embodiment, conditioning energy is delivered to the target treatment area
which elevates temperatures in
at least a portion of the treatment area, such as to 45 degrees Celsius. This
induces extravasation of fluid
to the area. A drug, gene, or other type of molecule is delivered via
intratumoral injection and benefits
from the advantages of extravasation as describe herein. Therapy, such as
therapeutic PEF energy is then
delivered to the target treatment area. Since the cells of the treatment area
were previously conditioned to
resist cell death, a greater number of cells survive the treatment protocol.
This is beneficial for gene
therapy or other types of therapy which rely on cell survival.
II. Delivery System Embodiments
[00164] As mentioned, the devices, systems and methods described herein
generate extravasation and
interstitial edema by delivering pulsed electric field (PEF) or other mixed-
lethal or sub-lethal energy to
the target tissue area which induces alterations, such as in the endothelial
walls of capillaries within and
optionally near the target tissue area. Fig. 13 illustrates an embodiment of
an energy delivery system 100
for delivering such PEF energy to the target tissue area. In this embodiment,
the system 100 comprises a
specialized energy delivery device 102, a return electrode 106, and a waveform
generator 104. In this
embodiment, the target tissue area is located within a liver LR of a patient
P. however it may be
appreciated that such devices, systems and methods may be used to treat target
tissue areas throughout the
body. In this embodiment, the energy delivery device 102 comprises a flexible
elongate shaft having a
distal end capable of being advanced endoluminally to the target tissue within
the liver LR. As shown,
the distal end of the delivery device 102 is advanced through the mouth M,
down the esophagus E, into
the stomach S wherein it passes through the stomach wall into the liver LR. In
some embodiments, the
-21 -
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
distal end has a distal tip 103 configured to penetrate the stomach wall
and/or the liver LR. In other
embodiments, a passageway is formed through the stomach wall with the use of a
separate instrument
which is then removed so that an energy delivery device 102 having an
atraumatic tip is able to be passed
through the passageway. It may be appreciated that in other embodiments the
energy delivery device 102
is percutaneous.
[001651 Examples of systems which may provide this type of therapeutic
treatment are provided in
commonly assigned patent application PCT/US2020/028844, entitled -DEVICES,
SYSTEMS AND
METHODS FOR THE TREATMENT OF ABNORMAL TISSUE", incorporated herein by
reference for
all purposes. Other example systems include the pulmonary tissue modification
systems (e.g., energy
delivery catheter systems) described in commonly assigned patent applications
including international
patent application number PCT/US2017/039527 titled "GENERATOR AND A CATHETER
WITH AN
ELECTRODE AND A METHOD FOR TREATING A LUNG PASSAGEWAY," which claims priority
to U.S. provisional application numbers 62/355,164 and 62/489,753,
international patent application
number PCT/US2018/067501 titled "METHODS, APPARATUSES, AND SYSTEMS FOR THE
TREATMENT OF DISORDERS" which claims priority to U.S. Provisional Application
No. 62/610,430,
and international patent application number PCT/US2018/067504 titled
"OPTIMIZATION OF ENERGY
DELIVERY FOR VARIOUS APPLICATIONS" which claims priority to Provisional Patent
Application
No. 62/610,430 filed December 26, 2017 and U.S. Provisional Patent Application
No. 62/693,622 filed
July 3, 2018, all of which are incorporated herein by reference for all
purposes.
[001661 As mentioned, the conditioning PEF energy and optionally the
therapeutic energy is delivered
to the target tissue through the distal end of the delivery device 102. The
proximal end of the delivery
device 102 is electrically connected with the waveform generator 104. In some
embodiments, the
generator 104 is also connected with an external cardiac monitor to allow
coordinated delivery of energy
with the cardiac signal sensed from the patient P.
[00167] The energy is provided by the generator 104 and delivered to the
tissue through an energy
delivery body 108 placed on, in, or near the targeted tissue area. Electric
pulses are then delivered
through the energy delivery body 108 in the vicinity of the target tissue.
These electric pulses are
provided by at least one energy delivery algorithm 152. In such embodiments,
the algorithm 152
specifies parameters of the signal such as energy amplitude (e.g. voltage) and
duration of applied energy,
which is comprised of the number of pulses, the pulse widths and the delay
between pulses, to name a
few. In some embodiments, one or more of the energy delivery bodies arc small
and tend to dissipate
large amount of energy around the electrode. Therefore, an optimal delivery of
energy is desired.
Typically, large DC-link capacitance with half transistor bridges is the
recommended generator structure
to deliver efficient delivery pulses in such instances. Pulse voltages
delivered by power amplifiers
(limited bandwidth) or exponential decay generators are not as desirable for
this application.
[001681 In some embodiments, biphasic pulses may be used. In such embodiments,
additional
parameters may include switch time between polarities in biphasic pulses and
dead time between biphasic
-22-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
cycles. A feedback loop based on sensor information and an auto-shutoff
specification, and/or the like,
may be included. Biphasic waveforms are convenient to reduce muscle
stimulation in patients. This is
particularly important in the application where slight movement of the energy
delivery body can easily
result a non-effective procedure. Biphasic waveforms involve rapid change of
phases/polarities of the
signal to minimize nerve activation during transition between polarity.
Multiple fast switching elements
(e.g. MOSFET, IGBT Transistors) are desired and are employed and configured
in, for example, H-bridge
structure or full bridge.
[00169] Referring back to Fig. 13, in this embodiment the generator 104
includes a user interface 150,
one or more energy delivery algorithms 152, a processor 154, a controller 155,
a data storage/retrieval
unit 156 (such as a memory and/or database), and an energy-storage sub-system
158 which generates and
stores the energy to be delivered. In some embodiments, one or more capacitors
are used for energy
storage/delivery, however any other suitable energy storage element may be
used. In addition, one or
more communication ports may be included.
[001701 In some embodiments, the generator 104 includes three sub-systems: 1)
a high-energy storage
system, 2) a high-voltage, medium-frequency switching amplifier, and 3) the
system controller, firmware,
and user interface. The generator takes in alternating current (AC) mains to
power multiple direct current
(DC) power supplies. The generator's controller can cause the DC power
supplies to charge a high-
energy capacitor storage bank before energy delivery is initiated. In some
embodiments, at the initiation
of energy delivery, the generator's controller, high-energy storage banks and
a bi-phasic pulse amplifier
can operate simultaneously to create a high-voltage, medium frequency output.
[00171] It will be appreciated that a multitude of generator electrical
architectures may be employed to
execute the energy delivery algorithms. In particular, in some embodiments,
advanced switching systems
are used which are capable of directing the pulsed electric field circuit to
the energy delivering electrodes
separately from the same energy storage and high voltage delivery system.
Further, generators employed
in advanced energy delivery algorithms employing rapidly varying pulse
parameters (e.g., voltage,
frequency, etc.) or multiple energy delivery electrodes may utilize modular
energy storage and/or high
voltage systems, facilitating highly customizable waveform and geographical
pulse delivery paradigms. It
should further be appreciated that the electrical architecture described
herein above is for example only,
and systems delivering pulsed electric fields may or may not include
additional switching amplifier
components.
[00172] The user interface 150 can include a touch screen and/or more
traditional buttons to allow for
the operator to enter patient data, select a treatment algorithm (e.g., energy
delivery algorithm 152),
initiate energy delivery, view records stored on the storage/retrieval unit
156, and/or otherwise
communicate with the generator 104.
[00173] In some embodiments, the user interface 150 is configured to receive
operator-defined inputs.
The operator-defined inputs can include a duration of energy delivery, one or
more other timing aspects
of the energy delivery pulse, power, and/or mode of operation, or a
combination thereof Example modes
-23 -
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
of operation can include (but arc not limited to): system initiation and self-
test, operator input, algorithm
selection, pre-treatment system status and feedback, energy delivery, post
energy delivery display or
feedback, treatment data review and/or download, software update, or any
combination or
subcombination thereof.
[00174] In some embodiments, the processor 154, among other activities,
modifies and/or switches
between the energy-delivery algorithms, monitors the energy delivery and any
sensor data, and reacts to
monitored data via a feedback loop. In some embodiments, the processor 154 is
configured to execute
one or more algorithms for running a feedback control loop based on one or
more measured system
parameters (e.g., current), one or more measured tissue parameters (e.g.,
impedance), and/or a
combination thereof.
[00175] The data storage/retrieval unit 156 stores data, such as related to
the treatments delivered, and
can optionally be downloaded by connecting a device (e.g., a laptop or thumb
drive) to a communication
port. In some embodiments, the device has local software used to direct the
download of information,
such as, for example, instructions stored on the data storage/retrieval unit
156 and executable by the
processor 154. In some embodiments, the user interface 150 allows for the
operator to select to download
data to a device and/or system such as, but not limited to, a computer device,
a tablet, a mobile device, a
server, a workstation, a cloud computing apparatus/system, and/or the like.
The communication ports,
which can permit wired and/or wireless connectivity, can allow for data
download, as just described but
also for data upload such as uploading a custom algorithm or providing a
software updatc.
[00176] As described herein, a variety of energy delivery algorithms 152 are
programmable, or can be
pre-programmed, into the generator 104, such as stored in memory or data
storage/retrieval unit 156.
Alternatively, energy delivery algorithms can be added into the data
storage/retrieval unit to be executed
by processor 154. Each of these algorithms 152 may be executed by the
processor 154.
[00177] In some embodiments, the energy delivery device 102 includes one or
more sensors that can
be used to determine temperature, impedance, resistance, capacitance,
conductivity, pH, optical properties
(coherence, echogenicity, fluorescence), electrical or light permittivity,
and/or conductance, to name a
few. In some embodiments, one or more of the electrodes act as the one or more
sensors. In other
embodiments, the one or more sensors are separate from the electrodes. Sensor
data can be used to plan
the procedure, monitor the procedure and/or provide direct feedback via the
processor 154, which can
then alter the energy-delivery algorithm 152. For example, impedance
measurements can be used to
determine not only the initial dose to be applied but can also be used to
determine the need for further
energy delivery, or not.
[00178] It may be appreciated that in some embodiments the system 100 includes
an automated
delivery algorithm that dynamically responds and adjusts and/or terminates
delivery in response to inputs
such as temperature, impedance at various voltages or AC frequencies, time
duration or other timing
aspects of the energy delivery pulse, power and/or system status.
-24-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00179] In this embodiment, molecules 110 are delivered systemically,
intravenously with the use of
an IV bag 112. This typically disperses the molecules throughout the body of
the patient P. including to
the target tissue within the liver LR. It may be appreciated that in other
embodiments, the molecules 110
are delivered regionally. In such embodiments, the molecules 110 may be
delivered to the vasculature,
upstream of the arterial system that leads to the targeted organ or tissue
area. The molecules 110 then
travel through the downstream arterial circulation into the targeted region.
If a bolus injection of the
molecules 110 is provided, a sudden rush of molecules 110 will enter into the
targeted tissue. However, if
the molecules 110 are delivered over time, such as with the use of an infusion
pump, a steady, sustained
level of molecules 110 may be achieved in the targeted tissue. It may be
appreciated that in other
embodiments, the molecules 110 are delivered by direct injection to the
targeted tissue. In such
embodiments, the injection device is inserted in or near the targeted tissue,
such as within the
parenchymal tissue of the targeted organ region, and a solution containing the
molecules 110 is injected.
It may be appreciated that any combination of systemic, regional and local
delivery may alternatively be
used.
[00180] In some embodiments, the conditioning PEF energy is delivered prior
to, during and/or after
delivery of the molecules 110, but before the therapeutic treatment, so as to
improve the later uptake or
effect of the molecules 100 on the cells within the target tissue area. Thus,
it may be understood that the
molecules 110 can be delivered before, during and/or after delivery of the
conditioning PEF. In other
embodiments, the conditioning PEF energy and the treatment PEF energy are one
in the same and in such
instances the molecules 110 may be delivered before, during and/or after the
delivery of the treatment
PEF energy. Various methodologies of timing and procedure will be described in
greater detail in later
sections.
IlL Molecules and Enhancements
[00181] As mentioned previously, in some embodiments the devices, systems and
methods are
provided for delivering molecules 110, particularly small molecules and/or
macromolecules, to cells
within the body, such as to target cells. In some embodiments, the cells
directly therapeutically benefit
from the functionality of the molecules. Such therapeutic benefit may be in
the treatment of a variety of
disorders.
[00182] In some embodiments, the disorder comprises a coagulation disorder,
such as hemophilia (e.g.,
hemophilia A or hemophilia B), von Willebrand's disease, factor XI deficiency,
a fibrinogen disorder, or
a vitamin K deficiency. The coagulation disorder may be characterized by a
mutation in a gene encoding
for fibrinogen, prothrombin, factor V, factor VII, factor VIII, factor X,
factor XI, factor XIII, or an
enzyme involved in posttranslational modifications thereof, or an enzyme
involved in vitamin K
metabolism. In some embodiments, the coagulation disorder is characterized by
a mutation in FGA,
FGB, FGG, F2, F5, F7, F10, F11, F13A, F13B, LMAN1, MCFD2, GGCX, or VKORC1.
-25-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00183] In some embodiments, the disorder comprises a neurological disorder,
e.g., a
neurodegenerative disease. In some embodiments, the neurodegenerative disease
comprises Alzheimer's
disease, Parkinson's disease, or multiple sclerosis. In some embodiments, the
neurodegenerative disease
comprises an autoimmune disease of the central nervous system (CNS), such as
multiple sclerosis,
encephalomyelitis, a paraneoplastic syndrome, autoimmune inner ear disease, or
opsoclonus myoclonus
syndrome. The neurological disorder may be a cerebral infarction, spinal cord
injury, central nervous
system disorder, a neuropsychiatric disorder, or a channelopathy (e.g.,
epilepsy or migraine). The
neurological disorder may be an anxiety disorder, a mood disorder, a childhood
disorder, a cognitive
disorder, schizophrenia, a substance related disorders, or an eating disorder.
In some embodiments, the
neurological disorder is a symptom of a cerebral infarction, stroke, traumatic
brain injury, or spinal cord
injury.
[00184] In some embodiments, the disorder comprises a lysosomal storage
disorder, such as Tay-Sachs
disease, Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease,
or
mucopolysaccharidosis (MPS).
[00185] In some embodiments, the disorder comprises a cardiovascular disorder,
such as a
degenerative heart disease, a coronary artery disease, an ischemia, angina
pectoris, an acute coronary
syndrome, a peripheral vascular disease, a peripheral arterial disease, a
cerebrovascular disease, or
atherosclerosis. The cardiovascular disorder may be a degenerative heart
disease selected from the group
consisting of an ischemic cardioniyopathy, a conduction disease, and a
congenital defect.
[00186] In some embodiments, the disorder comprises an immune disorder, e.g.,
an autoimmune
disorder. The autoimmune disorder may be type 1 diabetes, multiple sclerosis,
rheumatoid arthritis,
lupus, encephalomyelitis, a paraneoplastic syndrome, autoimmune inner ear
disease, or opsoclonus
myoclonus syndrome, autoimmune hepatitis, uveitis, autoimmune retinopathy,
neuromyelitis optica,
psoriatic arthritis, psoriasis, myasthenia gravis, chronic Lyme disease,
celiac disease, chronic
inflammatory demyelinating polyneuropathy, peripheral neuropathy,
fibromyalgia, Hashimoto 'S
thyroiditis, ulcerative colitis, or Kawasaki disease.
[00187] In some embodiments, the disorder comprises a liver disease, such as
hepatitis, Alagille
syndrome, biliary atresia, liver cancer, cirrhosis, a cystic disease, Carolls
syndrome, congenital hepatic
fibrosis, fatty liver, galactosemia, primary sclerosing cholangitis,
tyrosinemia, glycogen storage disease,
Wilson's disease, or an endocrine deficiency. The liver disease may be a liver
cancer such as a
hepatocellular hyperplasia, a hepatocellular adenoma, a focal nodular
hyperplasia, or a hepatocellular
carcinoma.
[00188] In some embodiments, the disorder comprises a cancer, such as a blood
cancer (e.g., acute
lymphoblastic leukemia, acute myeloblastic leukemia, chromic myelogenous
leukemia, Hodgkin's
disease, multiple myeloma, and non-Hodgkin's lymphoma) or a solid tissue
cancer (e.g., liver cancer,
kidney cancer, a breast cancer, a gastric cancer, an esophageal cancer, a
stomach cancer, an intestinal
cancer, a colorectal cancer, a bladder cancer, a head and neck cancer, a skin
cancer, or a brain cancer).
-26-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00189] In some embodiments, the disorder comprises a recessively inherited
disorder. In some
embodiments, the disorder is a Mendelian-inherited disorder.
[001901 In some embodiments, the disorder comprises an ocular disorder that is
a retinal dystrophy
(e.g., a Mendelian-heritable retinal dystrophy). The retinal dystrophy may be
comprised of leber's
congenital amaurosis (LCA), Stargardt Disease, pseudoxanthoma elasticum, rod
cone dystrophy,
exudative vitreoretinopathy, Joubert Syndrome, CSNB-1C, age-related macular
degeneration, retinitis
pigmentosa, stickler syndrome, microcephaly and choriorretinopathy, retinitis
pigmentosa, CSNB 2,
Usher syndrome, or Wagner syndrome.
[001911 In some embodiments, the molecules 110 delivered by the devices,
systems and methods
described herein include synthetic DNA vectors, such as those described in
Publication No.
W02019178500 filed on March 15, 2019, entitled "Synthetic DNA Vectors and
Methods of Use,"
incorporated in its entirety herein for all purposes. Such synthetic DNA
vectors include non-viral DNA
vectors, such as those that provide long-term transduction of quiescent cells
(e.g., post-mitotic cells) in a
manner similar to AAV vectors. In some embodiments, such non-viral DNA vectors
are development by
an in vitro (e.g., cell-free) system to synthetically produce circular AAV-
like DNA vectors (e.g., DNA
vectors containing a terminal repeat sequence, such as a DD element) by
isothermal rolling-circle
amplification and ligation-mediated circularization (as opposed to bacterial
expression and site-specific
recombination, for example). Such development allows for improved scalability
and manufacturing
efficiency in production of circular AAV-like DNA vectors. Moreover, the
vectors produced by these
methods are designed to overcome many of the problems associated with plasmid-
DNA vectors, e.g.,
problems discussed in Lu et al., Mol. Ther. 2017, 25(5): 1187-98, which is
incorporated herein by
reference in its entirety. For example, by eliminating or reducing the
presence of CpG islands and/or
bacterial plasmid DNA sequences such as RNAPII arrest sites, transcriptional
silencing can be reduced or
eliminated, resulting in increased persistence of the heterologous gene.
Further, by eliminating the
presence of immunogenic components (e.g., bacterial endotoxin, DNA, or RNA, or
bacterial signatures,
such as CpG motifs), the risk of stimulating the host immune system is
reduced. Such benefits are
especially advantageous in the treatment of certain disorders, such as retinal
dystrophies (e.g., Mendelian-
heritable retinal dystrophies).
[001921 Thus, such vectors include synthetic DNA vectors that: (i) are
substantially devoid of bacterial
plasmid DNA sequences (e.g., RNAPII arrest sites, origins of replication,
and/or resistance genes) and
other bacterial signatures (e.g., immunogenic CpG motifs); and/or (ii) can be
synthesized and amplified
entirely in a test tube (e.g., replication in bacteria is unnecessary, e.g.,
bacterial origins of replication and
bacterial resistance genes are unnecessary). In some embodiments, the vectors
contain a double-D (DD)
element characteristic of AAV vectors. This allows a target cell to be
transduced with a DNA vector
having a heterologous gene that behaves like AAV viral DNA (e.g., having low
transcriptional silencing
and enhanced persistence), without needing the virus itself.
-27-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00193] In some embodiments, the molecules 110 include nucleic acid-based
molecules, such as small
interfering RNA (siRNA), short hairpin RNA (shRNA), oligonucleotides,
antisense oligonucleotide
(ASO), microRNA (miRNA), decoy DNA, ribozyme, morpholino and plasmid.
[00194] RNA interference using small inhibitory RNA (siRNA) can be used to
downregulate mRNA
levels by cellular nucleases that become activated when a sequence homology
between the siRNA and a
respective mRNA molecule is detected. Therefore, in some embodiments, siRNA is
used to silence genes
involved in the pathogenesis of various diseases associated with a known
genetic background. In some
embodiments, the molecules 110 comprise Patisiran, an siRNA-based drug FDA
approved for the
treatment of polyneuropathy in people with hereditary transthyretin-mediated
amyloidosis. In order for
the siRNA to function, the siRNA must be inside the target cell of interest.
This means the siRNA must
be transported to the tissue in the body where the target cells reside and
then it must cross through the
cell's membrane. These requirements are generally referred to as "delivery- of
the siRNA to the desired
location. Delivery has proved difficult in conventional delivery methods
because siRNAs are negatively
charged molecules that do not naturally cross through a cell's outer membrane.
The devices, systems and
methods described herein overcome these delivery difficulties, delivering the
siRNA into the target cells.
[00195] In some embodiments, the molecules 110 include microRNAs (miRNAs).
miRNAs are a class
of small noncoding RNAs of ¨22nt in length which are involved in the
regulation of gene expression at
the posttranscriptional level by degrading their target mRNAs and/or
inhibiting their translation.
[00196] In some embodiments, the molecules 110 include antisense
oligonucleotides (ASO). ASOs
are synthetic DNA oligomers that hybridize to a target RNA in a sequence-
specific manner. In some
embodiments, ASOs are delivered to inhibit gene expression, modulate splicing
of a precursor messenger
RNA, or inactivate microRNAs. In order to stabilize ASO against nucleolytic
degradation, chemically
modified nucleotides such as phosphorothioates, 2'-0-methyl RNA, or locked
nucleic acids may be used
because they confer nuclease resistance. In some embodiments, ASOs are
delivered with optimization of
enhanced delivery, specificity, affinity, and nuclease resistance with reduced
toxicity.
[00197] Example ASOs include (1) Fomivirsen, such as for treatment of CMV
retinitis in AIDS
patients, (2) Mipomersen, such as for treatment of familial
hypercholcsterolcmia, (3) defibrotidc, such as
for treatment of veno-occlusive disease in the liver, (4) Eteplirsen, such as
for the treatment of Duchenne
muscular dystrophy, (5) pegaptanib, such as for the treatment of neovascular
age-related macular
degeneration, and (6) Nusinersen, such as for the management of spinal
muscular atrophy.
[00198] In some embodiments, the molecules 110 include oligomer molecules,
such as
phosphorodiamidate Morpholino oligomer (PMO), also known as Morpholino, a type
of oligomer
molecule used to modify gene expression knocking down gene function. Usually
25 bases in length,
Morpholinos bind to complementary sequences of RNA or single-stranded DNA by
standard nucleic acid
base-pairing. A Morpholino oligo specifically binds to its selected DNA or RNA
target site to block
access of cell components to that site. This property can be exploited to
block translation, block splicing,
block microRNAs (miRNAs) or their targets, and block ribozyme activity. Its
molecular structure
-28-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
contains DNA bases attached to a backbone of methylenemorpholine rings linked
through
phosphorodiamidate groups. Because the uncharged backbone of the Morpholino
oligo is not recognized
by enzymes, it is completely stable to nucleases. In some embodiments, the
Morpholino-based drug,
eteplirsen, is delivered which may be used in the treatment of some mutations
causing Duchenne
muscular dystrophy (DMD). In other embodiments, the Morpholino-based drug,
golodirsen, is delivered
for DMD treatment.
[00199] In some embodiments, the molecules 110 include ribozymes (ribonucleic
acid enzymes) which
are naturally occurring RNA molecules that catalyze specific biochemical
reactions, including RNA
splicing in gene expression, similar to the action of protein enzymes. In some
embodiments, the
molecules 110 comprise synthetic ribozymcs, such as designed to inhibit the
production of proteins
through the specific cleavage of the disease-causing mRNA. Another application
of ribozyme therapy
includes the inhibition of RNA-based viruses such as HIV, hepatitis C virus,
SARS coronavirus (SARS-
CoV), Adenovirus and influenza A and B virus.
[002001 In some embodiments the molecules 110 comprise a ribonucleoprotein
(RNP). RNP is a
complex formed between RNA and RNA-binding proteins. For instance, purified
Cas9 Protein can be
combined with guide RNA to form an RNP complex to be delivered to cells for
rapid and highly efficient
genome editing. RNPs remain in the cell for a short time and the dose is
minimal, leading to lower
toxicity and reduced editing at off-target sites compared to other methods.
RNP complex are also DNA-
free lacking therefore insertional mutagenesis risks.
[00201] In some embodiments, the molecules 110 delivered by the devices,
systems and methods
described herein include Clustered Regularly Interspaced Short Palindromic
Repeats Repetitive
(CRISPR) DNA sequences, called CRISPR. These DNA sequences were originally
observed in bacteria
with -spacer" DNA sequences in between the repeats that exactly match viral
sequences. It was
subsequently discovered that bacteria transcribe these DNA elements to RNA
upon viral infection. The
RNA guides a nuclease (a protein that cleaves DNA) to the viral DNA to cut it,
providing protection
against the virus. The nucleases are named -Cas," for "CRISPR-associated."
[00202] In 2012, researchers demonstrated that RNAs could be constructed to
guide a Cas nuclease
(Cas9 was the first used) to any DNA sequence. The so-called guide RNA can
also be made so that it will
be specific to only that one sequence, improving the chances that the DNA will
be cut at that site and
nowhere else in the genome. Further testing revealed that the system works
quite well in all types of cells,
including human cells
[00203] With CRISPR/Cas, a targeted gene is able to be disrupted, or, if a DNA
template is added to
the mix, a new sequence is able to be inserted at a precise spot desired. The
method has been used to
develop animal models with specific genomic changes. And for htu-nan diseases
with a known mutation,
such as cystic fibrosis, it is theoretically possible to insert DNA that
corrects the mutation. However, it
has been difficult to deliver the CRISPR/Cas material to mature cells in large
numbers using conventional
-29-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
methods such as viral vectors. However, the devices, systems and methods
described herein overcome
these difficulties allowing molecules 110 comprising CRISPR/Cas material to be
delivered to cells.
[00204] In some embodiment the molecules 110 comprise recombinant protein.
With the use of
recombinant DNA technology, such therapeutic proteins have been developed to
treat a wide variety of
disease, including cancers, autoimmunity/inflammation, exposure to infectious
agents, and genetic
disorders.
[00205] In some embodiments the molecules 110 comprise a proteolysis targeting
chimera (PROTAC).
PROTAC is a small molecule capable of removing specific unwanted proteins.
PROTACs are comprised
of two covalently linked protein-binding molecules: one capable of engaging an
E3 ubiquitin ligase, and
another that binds to a target protein meant for degradation. Recruitment of
the E3 ligase to the target
protein results in ubiquitination and subsequent degradation of the target
protein by the proteasome.
PROTACs may be employed in the degradation of different types of target
proteins related to various
diseases, including cancer, viral infection, immune disorders, and
neurodegenerative diseases.
[00206] PROTAC has various advantages in cancer therapy such as overcoming
drug resistance and
degrade traditionally "undruggable" protein target. At present, only 20-25% of
the known protein targets
can be targeted by using conventional drug discovery technologies. The
proteins that lack catalytic
activity and/or have catalytic independent functions arc still regarded as
"undruggable" targets. Moreover,
large amount of oncoproteins, such as transcriptional factors, chromatin
modulators and small GTPases,
are hard to be directly targeted pharmaceutically.. PROTAC is designed to
target protein of interest
(usually oncoprotein) for degradation by hijacking the endogenous E3 ligase
and ubiquitin proteasome
system.
[00207] In some embodiments, the molecules 110 are comprised of antineoplastic
drugs such as
chemotherapy. Chemotherapy drugs include agents such as alkylating compounds
(e.g. Cisplatin),
nitrosoureas (e.g. Carmustine), anti-metabolites (e.g. Fluorouracile),
alkaloids (e.g. Taxol), antibiotics
(e.g. Doxorubicin), Corticosteroid hormones and sex hormones (e.g.
Dexamethasone and Tamoxifen),
topoisomerase inhibitors (e.g. Etoposide) and retinoids (e.g. all trans
retinoid acid ATRA).
[00208] In some embodiments, the molecules 110 comprise immunotherapy drugs
such as checkpoint
inhibitors. Immune checkpoint inhibitors work by blocking checkpoint proteins
from binding with their
partner proteins. This prevents the "off' signal from being sent, allowing the
T cells to kill cancer cells.
[00209] In some embodiments, the molecules 110 are immunotherapy drugs such as
T-cell transfer
therapy. This therapy enhances the ability of the body's T cells to fight
cancer. Immune cells arc extracted
from the tumor and those identified as the most active against the tumor are
further modified to better
attack the cancer cells. Once enough cells have been grown, the cells are
injected back into the body to
fight the disease.
[00210] In some embodiments, the molecules 110 comprise immunotherapy drugs
such as cancer
vaccines. These vaccines are administered to trigger an immune response
against certain cancers. This
boosts the immune system's response against the cancer cells. Example cancer
vaccines include the
-30-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
following vaccines approved by the U.S. Food and Drug Administration that
prevent cancer: 1) HPV
vaccine, this vaccine protects against the human papillomavirus (HPV) which
predispose to cervical
cancers. 2) Hepatitis B vaccine to protect against the hepatitis B virus (HBV)
which causes liver cancer.
[00211] In some embodiments, the molecules 110 comprise immune system
modulators. Types of
immune-modulating agents include: Cytokines (e.g. interferons, interleukins)
and Immunomodulatory
drugs (e.g. Thalidomide).
[00212] In some embodiments, the molecules 110 comprise monoclonal antibodies.
Monoclonal
antibodies (mAbs) are lab-created immune system proteins (antibodies) that are
designed to bind to
specific proteins on cancer cells. These proteins bind to the cancer cells,
allowing them to be recognized
and destroyed by the immune system. Many monoclonal antibodies are used to
treat cancer (e.g. Avastin,
Herceptin). Some monoclonal antibodies are also immunotherapy because they
help turn the immune
system against cancer (e.g. anti PD-1, anti-PDL-1, anti-CTLA-4, anti- CD20,
anti-CD19).
[00213] The ability to deliver the molecules 110 to the tissue or cells may be
altered with the use of a
variety of enhancements. For example, in some embodiments, ancillary/auxiliary
materials are added to
the body, such as added to a solution carrying the molecules, wherein the
auxiliary materials render the
cells more susceptible to small molecule or macromolecule uptake. Example
auxiliary materials include
polymeric nanoparticles, liposomes, PEGylated liposomes, lipofectamine, cell-
penetrating peptides
(CPC), dimethyl sulfoxide (DMSO), cholesterol, or other materials known to
interact with cell membrane
fluidity and mechanics. In sonic embodiments, the auxiliaiy material is
injected, and the injection
pressure is chosen or adjusted to enhance uptake of the molecules 110 by the
cells.
[00214] In other embodiments, the tissue or cells are warmed or cooled to
alter their ability to
successfully receive the molecules 110. For example, in some embodiments, the
cells are warmed or
cooled, such as by warming or cooling a solution carrying the molecules 110,
to invoke better transfer
efficiency or improved likelihood of cell survival following energy delivery.
In some embodiments,
warming of the cells may increase membrane fluidity and therefore increase
acceptance of the molecules
110. In other embodiments, cooling of the cells may increase rigidity and
potential formation of "cracks"
which increase acceptance of the molecules 110.
[00215] As mentioned previously, the processor 154, among other activities,
modifies and/or switches
between the energy-delivery algorithms, monitors the energy delivery and any
sensor data, and reacts to
monitored data via a feedback loop. In some embodiments, the processor 154 is
configured to execute
one or more algorithms for running a feedback control loop based on one or
more measured system
parameters, one or more measured tissue parameters, and/or a combination
thereof. In some
embodiments, the parameter includes temperature so that temperature is able to
be maintained within a
specific range by controlling the cadence of energy delivery. This may be
useful for enhancing cell
uptake, immune response, overall safety, etc.
[00216] It may be appreciated that enhancements may be applied before, during
or after delivery of the
molecules 110 and/or before, during or after delivery of the treatment energy.
In some embodiments,
-31 -
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
auxiliary material is administered to the patient at a desired interval during
a multi-function waveform,
such as between a short high pulse and a long low pulse of an asymmetric
waveform. This may assist in
driving or pushing the auxiliary material into the cells.
[00217] It may be appreciated that in some embodiments, isotonic or hypertonic
saline solution is
delivered to the treatment site to adjust local tonicity.
IV. Example Waveforms
[00218] In some embodiments, the conditioning PEF energy has a waveform
comprising monophasic,
long-duration (>5001.ts) pulses. Fig. 14A illustrates an example waveform of
such PEF energy provided
by an energy delivery algorithm 152 of the generator 104 used for inducing
extravasation. In this
embodiment, the waveform is comprised of a series of pulses 400, each having a
pulse width 402 and
amplitude (determined by the set voltage 404), wherein each pulse 400 is
separated by a delay 406. In
this embodiment, the pulse width is considered long duration and is greater
than 500 microseconds. In
this embodiment, the delay 406 between pulses 400 is in a range of lOns to
10s, including 10ns-100ns,
lms-100ms, 100ms-500ms, 500ms-1 second, 1-5 seconds, 5-10 seconds, lms, 500ms,
1 second, 2
seconds, 5 seconds. In Fig. 14A, two pulses 400 are illustrated, however
conditioning may be achieved
with one, two, three, four, five, six, seven, eight, nine, ten, or more than
ten pulses. In some
embodiments, this PEF energy is not designed to induce uptake of the molecules
110 by cells within the
target tissue area and therefore may utilize a range of pulse parameters (e.g.
voltage, frequency, inter-
pulse delays, etc.). However, it may be appreciated that in some embodiments,
the treatment energy itself
may be similar to that of Fig. 14A. In some embodiments, the waveform is
biphasic, such as illustrated in
Fig. 14B. Here, each pulse 400 is biphasic and has a pulse width 402 separated
by a delay 406. In this
embodiment, the pulse width 402 is again considered long duration and is
greater than 500 microseconds.
In this embodiment, the delay 406 between pulses 400 is in a range of ljts to
lsecond, such as ljis to
101.ts, 101.ts, lias to 100)is, 100i.ts, its to 250p, 250ps, its to 500ps,
500ps, lms, 2ms, 5ms or 1-5ms, to
name a few. It may be appreciated that in some embodiments, the pulses 400
reverse polarity such that
some pulses 400 have a positive amplitude and some pulses 400 have a negative
amplitude; such reverses
in polarity may be symmetric or asymmetric. It may also be appreciated that in
some embodiments, the
pulses 400 are grouped by polarity. It may be appreciated that any suitable
number of pulses may be
present in each group, and each group may have the same or differing numbers
of pulses. For example,
six positive pulses may be followed by two negative pulses or four positive
pulses may be followed by
one negative pulse. Thus, various combinations can be made. Such groupings may
be symmetrical or
non-symmetrical. Further, although Fig. 13 illustrates monopolar delivery
utilizing the specialized energy
delivery device 102 and return electrode 106, the PEF energy may be delivered
with bipolar electrodes,
such as bipolar electrode arrays.
[00219] Fig. 15A illustrates an example waveform provided by an energy
delivery algorithm 152 of the
generator 104 used for providing a therapeutic treatment. Rather than long-
duration (>500ns) pulses
-32-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
configured for inducing extravasation, these waveforms have short duration
pulses 0.5 ¨ 200 las which
may be combined in multiple manners to result in a cumulative on-time of 1-
200ps comprising a packet;
after which multiple packets may be delivered as configured for a treatment,
such as for ablating targeted
regions of tissue. It may be appreciated that such PEF energy may also induce
extravasation. In this
embodiment, the waveform is comprised of a series of low voltage, low
frequency pulses 800, each
having a pulse width 802 and amplitude (determined by the set voltage 804),
wherein each pulse 800 is
separated by a delay 806. Such a waveform may be suited for transfer of
genetic material to cells. In this
embodiment, three pulses 800 are illustrated, however transfer may be achieved
with one, two, three,
four, five, six, seven, eight, nine, ten, or more than ten pulses. It may be
appreciated that in some
embodiments, the pulses 800 reverse polarity such that some pulses 800 have a
positive amplitude and
some pulses 800 have a negative amplitude. It may also be appreciated that in
some embodiments, the
pulses 800 are grouped by polarity. For example, Fig. 15B illustrates an
example waveform provided by
an energy delivery algorithm 152 wherein two pulses 800' have a positive
polarity followed by two
pulses 800" that have a negative polarity. It may be appreciated that any
suitable number of pulses may
be present in each group, and each group may have the same or diffcring
numbers of pulses. For
example, six positive pulses may be followed by two negative pulses or four
positive pulses may be
followed by one negative pulse. Thus, various combinations can be made. Such
groupings may be
symmetrical or non-symmetrical. Likewise, the pulses 800 may have differing
characteristics, such as
differing amplitudes (determined by the set voltage 804) and pulse widths 802.
[00220] In some embodiments, the therapeutic energy is delivered in a
monopolar fashion and the
amplitude of each pulse or the set voltage 804 is 1-500V, 1-250V, 1-100V, 10-
100V, 10-70V, 10-50V,
10-40V, 10-30V, 10-20V, by, 20V, 30V, 40V, 50V, 60V, 70V, 80V 90V, 100V, to
name a few. The
voltages used and considered may be the tops of square-waveforms, may be the
peaks in sinusoidal or
sawtooth waveforms, or may be the RMS voltage of sinusoidal or sawtooth
waveforms.
[00221] It may be appreciated that the set voltage 804 may vary depending on
whether the energy is
delivered in a monopolar or bipolar fashion. In bipolar delivery, a lower
voltage may be used due to the
smaller, more directed electric field. The bipolar voltage selected for use in
therapy is dependent on the
separation distance of the electrodes, whereas the monopolar electrode
configurations that use one or
more distant dispersive pad electrodes may be delivered with less
consideration for exact placement of the
catheter electrode and dispersive electrode placed on the body. In monopolar
electrode embodiments, the
dispersive electrode may be comprised of a pad or any other recipient
electrode. Typically, it functions as
a dispersive electrode due to its size (large enough to prevent invoking
effects locally where it is placed)
and/or due to its placement (far enough away to avoid local effects and to not
risk electrical arcing).
However, in some embodiments, the dispersive electrode is small and may have
some effects at its
placement site, however such effects may be benign collateral effects. For
example, the delivered
molecules 110 may not be present near the dispersive electrode so as to avoid
delivery or any delivery in
the area is inconsequential. In monopolar electrode embodiments, larger
voltages are typically used due
-33 -
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
to the dispersive behavior of the delivered energy through the body to reach
the dispersive electrode, on
the order of 10cm to 100cm effective separation distance. However, it may be
appreciated that separation
distance may be as low as 2cm-5cm in some embodiments, with typically 5cm
being the minimum for a
reasonably sized dispersive electrode. Conversely, in bipolar electrode
configurations, the relatively close
active regions of the electrodes, on the order of 0.5mm to 10cm, including lmm
to lcm, results in a
greater influence on electrical energy concentration and effective dose
delivered to the tissue from the
separation distance.
[00222] In some embodiments, the pulse width 802 is lms, 2ms, 5ms, 10ms, 20ms,
30 ms, 40ms,
50ms, 60ms, 70ms, 80ms, 90ms, 100ms, lms-100ms, 2ms-100ms, 1-2ms, to name a
few. In some
embodiments, the delay between pulses is 0.01-5 seconds, 0.01-0.1 seconds,
0.01-0.5 seconds, 0.01-1
second, 0.5 seconds, 0.5-1 second, 1 second, 1-1.5 seconds, 1-2 seconds, 0.5
to 2 seconds, 2 seconds, 1-3
seconds, to name a few. In some embodiments, the number of pulses is 1 pulse,
2 pulses, 3 pulses, 4
pulses, 5 pulses, 6 pulses, 7 pulses, 8 pulses, 9 pulses, 10 pulses, more than
10 pulses to name a few.
[00223] In some embodiments, the therapeutic energy comprises a series of high
voltage, high
frequency pulses are followed by a series of low voltage, low frequency pulses
wherein the combination
has particular effects on the target cells. For example, as illustrated in
Fig. 16A, a first set of pulses 820 is
delivered wherein the first set of pulses 820 comprises a plurality of high
voltage, high frequency pulses,
optionally in packets. Examples of such high voltage, high frequency pulses
are provided in US Patent
No. 10,702,337, entitled "Methods, apparatuses, and systems for the treatment
of pulmonary disorders"
and PCT/US2020/028844, entitled "DEVICES, SYSTEMS AND METHODS FOR THE
TREATMENT
OF ABNORMAL TISSUE", incorporated herein by reference, to name a few. Such
pulses may prepare
the cells for uptake of molecules 110 by the cells. In some embodiments, the
first set of pulses 820 is
followed by a delay 822 (such as 100 microseconds to 2 seconds) which is then
followed by a second set
of pulses 824. In this embodiment, the second set of pulses 824 is comprised a
plurality of low voltage,
low frequency pulses. Fig. 16A illustrates a first pulse 826 of the second set
of pulses 824 lasting up to
microseconds followed by a delay 806 (e.g. up to lms) and then a second pulse
828. In this
embodiment, the second pulse 828 has opposite polarity to the first pulse 826,
therefore the delay 806
may be considered a switch time delay 807. It may be appreciated that in some
embodiments, there is no
delay 806/807 between the pulses 826, 828. In some instances, the first set of
pulses 820 prepares the
cells for the uptake of molecules 110, such as putting them into a state that
is more receptive to receiving
the molecules or a transfer process. Thus, the first set of pulses 820 starts
the process. The second set of
pulses 824 then assist in getting the molecules into the cells, such as the
driving or pushing the molecules
into the cells. Optionally, these sets of pulses 820, 824 may be repeated in a
pattern.
[00224] Fig. 16B illustrates another example of waveform having varied
segments. Here, the first set
of pulses 820 is delivered wherein the first set of pulses 820 comprises a
plurality of high voltage, high
frequency pulses, optionally in packets. Again, examples of such high voltage,
high frequency pulses are
provided in US Patent No. 10,702,337, entitled -Methods, apparatuses, and
systems for the treatment of
-34-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
pulmonary disorders" and PCT/US2020/028844, entitled "DEVICES, SYSTEMS AND
METHODS FOR
THE TREATMENT OF ABNORMAL TISSUE", incorporated herein by reference, to name a
few. In
some embodiments, the first set of pulses 820 is followed by a delay 822 (such
as 100 microseconds to 2
seconds) which is then followed by a second set of pulses 824. In this
embodiment, the second set of
pulses 824 is comprised a plurality of low voltage, low frequency pulses. In
this embodiment, the second
set of pulses 824 is comprised of a series of biphasic pulses having no switch
time delay, wherein the
second set of pulses 824 lasts approximately 100 microseconds to 5
milliseconds. Again, in some
instances, the first set of pulses 820 prepares the cells for the uptake of
molecules 110, such as putting
them into a state that is more receptive to receiving the molecules or a
transfer process. Thus, the first set
of pulses 820 starts the process. The second set of pulses 824 then assist in
getting the molecules into the
cells, such as the driving or pushing the molecules into the cells.
Optionally, these sets of pulses 820, 824
may be repeated in a pattern.
[00225] Thus, in some embodiments, the system 100 includes an algorithm 152 to
generate a
waveform having a first set of pulses 400 designed to induce extravasation
followed (optionally after a
significant delay to allow time for the edema effect to maximally occur) by a
second set of pulses 800
designed to provide therapeutic treatment. When the therapeutic treatment
involves uptake of molecules
110 by the target cells, the second set of pulses 800 are typically configured
to increase uptake of the
molecules 110. In sonic embodiments, the therapeutic treatment involves
intracellular transfection of
genetic material into cells. Considerations for this objective include the
need to move the large,
oftentimes electrically charged, genetic materials to the surface of the cells
at the cell membranes, as well
as pushing them across the cell membrane, with potential enhancement from
temporary disruptions to the
cell membrane integrity. This can be attained by longer duration, monophasic
or biphasic sequences of
PEFs. In this way the plasmid that is residing within the interstitial fluid
is introduced into the cells to
enact its downstream objectives.
[00226] Optionally, the second set of pulses 800 may comprise a plurality of
different types of pulses,
such as a set of pulses 820 comprising a plurality of high voltage, high
frequency pulses followed by a set
of pulses 826 comprising a plurality of low voltage, low frequency pulses. In
such instances, the overall
waveform may comprise three sets of pulses: 1) an extravasation inducing set
of pulses 400, 2) a set of
high voltage, high frequency pulses 820, and 3) a set of low voltage, low
frequency pulses 826. Such
combinations of pulses may maximize the uptake of molecules 110 by the target
cells.
[00227] It may be appreciated that the delivery of PEF energy for
extravasation and therapeutic
treatment may be supplemented with the inclusion of secondary methods of
fostering either of these
objectives. For instance, when the molecules 110 comprise plasmid, an agent
such as lipofectamine could
be mixed with the plasmid to encourage cellular uptake. This may enhance
transfection in regions that
were first bathed in the plasmid+lipofectamine mixture via extravasation
induction from the capillary
disrupting PEF energy.
-35-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00228] Typically, the conditioning PEF energy disrupts the capillaries with
minimal or no destruction
of target tissue cells. The extent and ratio of killed cells to disrupted
capillaries would vary with different
target organs and conditions being treated. For instance, in hepatic
applications, collateral cell death to the
hepatocytes is generally more tolerable due to the regenerative nature of this
organ. Thus, liver-targeted
PEF first (or second) wave protocols may have increased intensity (voltage,
lower frequency, longer
duration, more of them) in comparison to more sensitive organs to generate
regional edema to a larger
volume. Conversely, targets such as the brain or heart may not afford much
tolerance for collateral cell
death, and thus treatments in these target organs may involve using weaker
protocols that cause edema in
smaller volumes so as to prevent excessive cell death in these sensitive
organs.
[00229] In some embodiments, conditioning PEF energy is utilized in
conjunction with a therapeutic
treatment comprising ablation and/or an immunological response, either alone
or in combination with
molecules comprising drugs or agents, such as chemotherapeutic agents. In such
instances, extravasation
is induced by the conditioning PEF, such as to normalize the target tissue
area before therapeutic
treatment (such as to create a stable impedance environment) and/or expands
the target treatment area by
creating a virtual or fluid electrode. This may be particularly the case when
utilizing conditioning PEF
energy in combination with therapy without the inclusion of molecules for
uptake by the cells. Such
therapeutic treatments may include microwave ablation, radiofrequency
ablation, cryoablation, high
intensity focused ultrasound (HIFU), and/or pulsed electric field therapies.
Examples of systems and
waveforms which provide this type of ablative pulsed electric field
therapeutic treatment include the
pulmonary tissue modification systems (e.g., energy delivery catheter systems)
described in commonly
assigned patent applications including international patent application number
PCT/US2017/039527 titled
"GENERATOR AND A CATHETER WITH AN ELECTRODE AND A METHOD FOR TREATING A
LUNG PASSAGEWAY," which claims priority to U.S. provisional application
numbers 62/355,164 and
62/489,753, international patent application number PCT/US2018/067501 titled
"METHODS,
APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF DISORDERS" which claims priority
to U.S. Provisional Application No. 62/610,430, and international patent
application number
PCT/US2018/067504 titled "OPTIMIZATION OF ENERGY DELIVERY FOR VARIOUS
APPLICATIONS" which claims priority to Provisional Patent Application No.
62/610,430 filed
December 26, 2017 and U.S. Provisional Patent Application No. 62/693,622 filed
July 3,2018, all of
which are incorporated herein by reference for all purposes.
[00230] In some embodiments, the focal therapy is used in combination with
molecules 110, such as
drugs or agents. Thus, the conditioning extravasation and edema may improve
the focal therapy, the
uptake of the molecules 110 by the cells, or both. When the molecules 110 are
delivered in combination
with focal therapy, the molecules 110 may act as a neoadjuvant therapy.
Neoadjuvant therapies may be
used in cancer treatment and are delivered before the primary treatment, to
help reduce the size of a tumor
or kill cancer cells that have spread.
-36-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00231] In some embodiments, the molecules 110 comprise chemotherapeutic
drugs. Chemotherapy is
typically a systemic therapy that is introduced into the bloodstream, so it
is, in principle, able to address
cancer at any anatomic location in the body. Traditional chemotherapeutic
agents are cytotoxic by means
of interfering with cell division but cancer cells vary widely in their
susceptibility to these agents. To a
large extent, chemotherapy can be thought of as a way to damage or stress
cells, which may then lead to
cell death if apoptosis is initiated. Many of the side effects of chemotherapy
can be traced to damage to
normal cells that divide rapidly and are thus sensitive to anti-mitotic drugs,
particularly cells in the bone
marrow, digestive tract and hair follicles. Chemotherapy may also be
administered locally to the tumor
tissue.
[00232] In some embodiments, conditioning PEF energy is used to induce
extravasation and edema
which increases the concentration of chemotherapy in the target tissue area.
In addition, the target tissue
is treated with therapeutic PEF energy. Such treatment disrupts cellular
homeostasis, which can initiate a
programmed cell death-like effect which leads to permanent cell death or
priming of the cells for more
effective damage by the chemotherapy. Such priming provides a synergy between
the therapeutic PEF
treatment and the chemotherapy leading to outcomes that exceed either
treatment alone. Thus, such
combinatory treatment can lead to more effective treatment and greatly
improved responses.
[00233] In some embodiments, the PEF energy has a waveform and signal
parameters configured for
oncological treatments, particularly treatment of cancerous tumors. Fig. 17
illustrates an embodiment of
such a waveform 900 prescribed by an energy delivery algorithm 152. Here, two
packets are shown, a
first packet 902 and a second packet 904, wherein the packets 902, 904 are
separated by a rest period 906.
It may be appreciated that a plurality of packets is typically delivered to
the target tissue in the treatment
of a tumor. In this embodiment, each packet 902, 904 is comprised of a first
biphasic pulse (comprising a
first positive peak 908 and a first negative peak 910) and a second biphasic
pulse (comprising a second
positive peak 908 and a second negative peak 910). The first and second
biphasic pulses are separated
by dead time or an inter-cycle delay 912 (i.e., a pause) between each cycle.
In some embodiments, the
inter-cycle delay 912 is 250p-50001.1s, particularly 10043, and in other
embodiments the delay 912 is
longer such as 2000ns-5000p. In this embodiment, the biphasic pulses are
symmetric so that the set
voltage 916 is the same for the positive and negative peaks. Here, the
biphasic, symmetric waves are also
square waves such that the magnitude and time of the positive voltage wave is
approximately equal to the
magnitude and time of the negative voltage wave. The positive voltage wave
causes cellular
depolarization in which the normally negatively charged cell briefly turns
positive. The negative voltage
wave causes cellular hyperpolarization in which the cell potential is
negative.
[00234] In some embodiments, each high voltage pulse or the set voltage 916 is
between about 3000V-
6000V, such as 3000V-3300V, 3000V-3500V, 3000V-4000V, 3000V, 3100V, 3200V,
3300V, 3400V,
3500V, 3600V, 3700V, 3800V, 3900V, 4000V, 4100V, 4200V, 4300V, 4400V, 4500V,
4600V, 4700V,
4800V, 4900V, 5000V, 5100V, 5200V, 5300V, 5400V, 5500V, 5600V, 5700V, 5800V,
5900V, 6000V.
-37-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
It may be appreciated that the set voltage 916 may vary depending on whether
the energy is delivered in a
monopolar or bipolar fashion and such values are particular for monopolar
delivery.
[00235] The number of pulses per unit of time is the frequency. In some
embodiments, the signal has a
frequency in the range 100-600kHz, such as 100-200kHz, 100-300kHz, 100-400Hz,
100-500kHz, 400-
500kHz, 100kHz, 200kHz, 300kHz, 400kHz, 500kHz, 600kHz. In addition, in some
embodiments,
cardiac synchronization is utilized to reduce or avoid undesired cardiac
muscle stimulation. In some
embodiments, biphasic pulses are utilized to reduce undesired muscle
stimulation, particularly cardiac
muscle stimulation. It may be appreciated that even higher frequencies may be
used with components
which minimize signal artifacts.
[00236] The cycle count 920 is the number of cycles within each packet.
Referring to Fig. 17, the first
packet 902 has a cycle count 920 of two (i.e. two biphasic pulses). In some
embodiments, the cycle count
920 is set between 10-60 cycles per packet, including all values and subranges
in between. In some
embodiments, the cycle count 920 is 10 cycles, 20 cycles, 30 cycles, 40
cycles, 50 cycles, 60 cycles, 10-
20 cycles, 20-30 cycles, 30-40 cycles, 40-50 cycles, 50-60 cycles, including
all values and subranges in
between. In some embodiments, the on-time per packet is 70-100ps, including
701õts, 80us, 90ns, 100p.s.
Since a period is the time it takes for a signal to complete an on-and-off
cycle, the on-time of a cycle is
the time in which the cycle is "on". Likewise, the on-time per packet is the
sum of the on-times for the
cycles in the packet. The packet duration is the sum of the periods for a
packet which is based on the
frequency.
[00237] In some embodiments, the number of packets delivered during treatment
is in the range of 1-
1000 packets, typically 20-400 packets or 40-100 packets, including 50
packets, 100 packets, 150 packets,
200 packets, including all values and subranges in between. In some
embodiments, the time between
packets, referred to as the rest period or inter-packet delay 906, is
approximately 3-6 seconds, such as 3
seconds, 4 seconds, 5 seconds, 6 seconds, including all values and subranges
in between. In some
embodiments the signal is synced with the cardiac rhythm so that each packet
is delivered between
heartbeats, thus the rest periods coincide with the heartbeats. Thus, the rest
period 906 may vary, as the
rest period between the packets can be influenced by the cardiac
synchronization.
[00238] It may be appreciated that the specific settings to desirably alter
target tissue are dependent on
one another and the electrode design. "lherefore, the embodiments provided
herein depict specific
waveform examples, and it is within the scope of this invention to use
multiple waveforms and/or
characteristics in any combination to achieve the desired tissue effects
[00239] In some embodiments, the waveform of Fig. 17 induces extravasation and
can be used for this
purpose in addition to the purpose of treatment. A particular example of such
a waveform has a voltage
of 1400V, a frequency of 300kHz, 30 cycles, an on-time of 1001.1s, 100
packets, a cycle delay of 1000vis,
and packet delay of 3 seconds. Thus, the overall treatment time in this
example is approximately 5
minutes (i.e. 100 packets * 3 seconds= 300 seconds or approximately 5
minutes). This example will be
utilized to illustrate the various timing examples described in later
sections.
-38-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
Sensors
[00240] In some embodiments, the energy delivery device 102 includes one or
more sensors that can
be used to determine pressure, temperature, impedance, resistance,
capacitance, conductivity, pH, optical
properties (coherence, echogenicity, fluorescence), electrical or light
permittivity, and/or conductance, to
name a few. In some embodiments, one or more of the electrodes of the energy
delivery body 108 act as
the one or more sensors. In other embodiments, the one or more sensors are
separate from the electrodes.
Sensor data can be used to plan the therapy, monitor the therapy and/or
provide direct feedback via the
processor 154, which can then alter the energy-delivery algorithm 152.
A. Pressure Sensing
[00241] It may be appreciated that cells typically respond to mechanical
stimuli. One such type of
mechanical stimuli is pressure. In general, hydrostatic pressure is determined
by the interstitial fluid
volume and the general compliance of the targeted tissue interstitium.
Important to note that this is
variable for tissue types as some organs are encased within a more rigid/less
compliant structure (e.g.,
brain, kidney, etc.), while others are more free to expand/contract (e.g.,
lungs, muscle, skin, etc.).
Increasing hydrostatic pressure can increase permeability of local cell
membranes. Thus, it is often
beneficial to be mindful of the pressure that the target cells are facing,
particularly during local injection
of molecules 110. Consequently, in some embodiments, the energy delivery
device 102 includes a
pressure sensor. Pressure sensor measurements may be utilized to monitor edema
levels resulting from
extravasation, such as before, during and/or after injection of molecules 110
and treatment energy. Thus,
inducement of extravasation can be adjusted to reach desired edema levels at
particular times throughout
a treatment protocol.
[00242] A variety of pressure sensors 200 may be used. In some embodiments,
the pressure sensor
200 is disposed along a distal tip of the energy delivery device 102, such as
illustrated in Fig. 18A. Here,
the energy delivery device 102 comprises an energy delivery body 108 having a
needle shape, wherein
the energy delivery body 108 is at least partially covered by an insulative
sleeve 202. As illustrated,
molecules 110 are passed through the energy delivery body 108 to the nearby
target tissue area. This
allows the pressure sensor 200 to monitor the pressure during the injection of
the molecules 110 and
application of treatment energy. In other embodiments, the pressure sensor 200
is disposed along the
distal end of the energy delivery device 102 but proximal to the tip, such as
illustrated in Fig. 18B. Here,
the pressure sensor 200 is disposed along the insulative sleeve 202 that at
least partially covers the energy
delivery body 108. Having a relative pressure measurement at the tissue level
allows the user to
understand the distribution of the injected molecules 110 within the tissue.
Considering the injected
solution at a known pressure and flow rate (values able to be easily measured
near the proximal end of the
device 102), an additional relative measurement at the distal end will provide
the information to
-39-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
understand thc spatial distribution of thc molecules along thc target tissue
as well as the temporal pressure
profile.
[00243] In some embodiments, the pressure sensor 200 comprises a strain-gauge
transducer. Strain-
gauge transducers are typically characterized by exhibiting a change in their
fonn of output in response to
the measurand (i.e., strain, electrical resistance, or wavelength).
Sensitivity is determined by the relative
change of resistance with respect to length.
[00244] In other embodiments, the pressure sensor 200 comprises a diaphragm
displacement sensor.
Diaphragm displacement sensors are based on micro-electromechanical systems
technology, in which the
sensors have a bendable flat surface (diaphragm) over a sealed cavity. The
diaphragm bends or deforms in
response to the change in pressure. The resultant form of output can be
capacitance based or piezoelectric
transducer based. In some embodiments, a sensor 200 is placed at the distal
tip of the energy delivery
device 102, while its corresponding diaphragm is disposed proximal to the
sensor 200, thus enabling a
measurement of the pressure drop across the distance therebetween. In
instances where such placement
of a sensor is difficult, such as due to size restrictions, a pressure sensing
optical fiber may be preferred.
[00245] In some embodiments, the energy delivery device 102 includes an
expandable member 204
disposed along its distal end, such as illustrated in Fig. 18C. Here, the
expandable member 204 is
mounted on an insulative sleeve 202 that at least partially covers the energy
delivery body 108 having a
needle shape. Such positioning of the expandable member 204 can assist in
preventing reflow of the
solution of molecules 110 back up the pathway created by inserting the energy
delivery device 102. This
may improve the pressure distribution within the target tissue and therefore
overall delivery of the
molecules 110. The expandable member 204 may also prevent movement of the
needle-like energy
delivery body 108 during delivery of the PEF energy. In some embodiments, a
pressure sensor 200
mounted on the expandable member 204 monitors the pressure within the
expandable member 204. This
ensures proper inflation of the expandable member 204. Further, in some
embodiments, the pressure
sensor 200 monitors tissue pressure during infusion of molecules 110 and/or
PEF energy delivery.
Timing Embodiments
[00246] It may be appreciated that the timing of the PEF energy delivery and
the molecule 110
delivery may be optimized for improved outcomes, such as improved treatment of
abnormal tissue such
as a tumor. Fig. 19 illustrates three example timing embodiments for molecule
110 delivery in relation to
a treatment delivery. Here, the x-axis illustrates the timing of the REF
energy delivery; particular
demarcations include the start of a PEF energy delivery 950 protocol and the
end of the PEF energy
delivery 952 protocol. Such a protocol is considered sufficient to treat a
target tissue area, such as to treat
a tumor such as by killing all or a desired amount of the tumor. The waveform
described above (i.e.
having a voltage of 1400V, a frequency of 300kHz, 30 cycles, an on-time of
1001..ts, 100 packets, a cycle
delay of 1000vis, and packet delay of 3 seconds) will be used for illustration
purposes. In this example,
the time between the start and end of the treatment is approximately 5
minutes. Additional demarcations
-40-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
arc provided, such as a demarcation 954 at approximately 1/3 (33%) of the way
through the treatment and
a demarcation 956 at approximately 2/3 (66%) of the way through the treatment.
[00247] In the first example, molecules 110A are delivered near the start of
thc PEF energy delivery
950 and are continued to be delivered through a first portion of the PEF
energy delivery, such as through
the first 25-33% of the PEF energy delivery. In this example, the molecules
110A are delivered for
approximately 1.25-1.67 minutes. It may be appreciated that in some instances
the molecules 110A are
additionally delivered prior to the start of the PEF energy delivery 950 (as
indicated by dashed line 960A)
to ensure that the molecules 110A have arrived at the target tissue by the
time the PEF energy delivery
has begun. In some embodiments, the molecules 110A are delivered 10 seconds to
10 minutes prior to
delivery of PEF energy, typically 1 minute to 10 minutes prior to delivery of
PEF energy. It may be
appreciated that the molecules 110A may be delivered by the various methods
described herein, including
local injection, regional delivery and systemic delivery, such as intravenous
delivery. Delivery methods
such as systemic delivery may benefit from starting earlier than local
delivery given the dynamics. It may
be appreciated that a significant portion of the treatment effect (e.g.
extravasation and ablation) typically
occurs within the first 25-33% of the treatment time while the remaining PEF
energy delivery helps
reinforce the effect. Thus, aligning the molecule 110A delivery with this
period allows the molecules
110A to be available during this valuable time, thereby maximizing their
effect.
[00248] In the second example, molecules 110B' are delivered near the start of
the PEF energy
delivery 950 and arc continuously delivered through a first portion of the PEF
energy delivery, such as
through the first 25% of the PEF energy delivery. An additional delivery of
molecules 110B" is provided
before the end of the PEF energy delivery 950, such as to be delivered over
the last 25% of the PEF
energy delivery period. Thus, in this example, the molecules 110B' arc
delivered for approximately 1.25
minutes near the start of PEF energy delivery, are not delivered for 2.50
minutes and the molecules 110B"
are then delivered for approximately 1.25 minutes to the end of the PEF energy
delivery 952_ Again, it
may be appreciated that in some instances the molecules 110B' are additionally
delivered prior to the start
of the PEF energy delivery 950 (as indicated by dashed line 960B) to ensure
that the molecules 110B'
have arrived at the target tissue by the time the PEF energy delivery has
begun. It may be appreciated
that the molecules 110B', 110B" may be delivered by the various methods
described herein, including
local injection, regional delivery and systemic delivery, such as intravenous
delivery. Delivery methods
such as systemic delivery may benefit from starting earlier than local
delivery given the dynamics.
Again, it may be appreciated that a significant portion of the treatment
effect (e.g. extravasation and
ablation) typically occurs within the first 25-33% of the treatment time while
the remaining delivery helps
reinforce the effect. Thus, aligning the molecule delivery with this period
combines allows the molecules
to be available during this valuable time, thereby maximizing their effect. In
addition, the delivery of
molecules 110B" over a later portion of the PEF energy delivery period
enhances reinforcement of the
effect, such as a final push of molecules post extravasation allowing more of
the molecules 110B" to
settle within the treatment area.
-41 -
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
[00249] In the third example, molecules 110C are delivered near the start of
the PEF energy delivery
950 and are continuously delivered through the PEF energy delivery period to
the end of the PEF energy
delivery period 952. Thus, in this example, the molecules 110C are delivered
for approximately 5
minutes over the duration of the PEF energy delivery period. Again, it may be
appreciated that in some
instances the molecules 110C are additionally delivered prior to the start of
the PEF energy delivery 950
(as indicated by dashed line 960C) to ensure that the molecules 110C have
arrived at the target tissue by
the time the PEF energy delivery has begun. It may be appreciated that the
molecules 110C may be
delivered by the various methods described herein, including local injection,
regional delivery and
systemic delivery, such as intravenous delivery. Delivery methods such as
systemic delivery may benefit
from starting earlier than local delivery given the dynamics. Such continuous
delivery of molecules
110C, such as at a constant infusion rate, maximizes the coordinated
interaction of the molecules,
extravasation and ablation throughout the treatment. In some instances, this
combination yields the
strongest results. A slow and constant delivery of molecules 110C over the
course of the 5-minute PEF
energy delivery allows for more molecules 110C to slowly diffuse across tissue
with the added benefit of
shockwave-like mechanical force being emitted from the energy delivery device
with delivery of every
packet of PEF energy.
[00250] Fig. 20 provides results of a laboratory study illustrating this
phenomenon. In this study, a pig
was anesthetized prior to performing a laparotomy to expose the liver.
Cisplatin (0.1mg) was injected in
the pig liver and combincd with PEF energy delivery using three modalities: 1)
local injection of cisplatin
without delivery of PEF energy (CIS alone group), 2) cisplatin was injected in
a different area of pig liver
and PEF was delivered in the same location 2 minutes after the bolus of the
drug (bolus+ PEF group), 3)
cisplatin was delivered over the course of 5 minutes concomitantly with the
delivery of PEF (infusion+
PEF group). The liver was collected 2 hours after PEF delivery and the treated
areas were sectioned to
separate the core, the periphery and the outer periphery. To select in the
treated areas of the core, a 6mm
punch biopsy was used. To collect in the periphery, a lOmm punch biopsy was
used. And, to isolate the
outer periphery, a 15mm punch biopsy was used. The liver samples were analyzed
by mass spectrometry
(ICP-MS) to quantify the concentration of cisplatin. As shown in Fig. 20, the
highest concentration of
cisplatin, both in the core and periphery, was achieved when the drug and PEF
energy were delivered
simultaneously (infusion+ PEF group), particularly wherein the drug was
delivered throughout treatment
with PEF energy.
[00251] It may be appreciated that although the above timing examples of Fig.
19 arc provided in
terms of treatment time, relative timing of delivery of molecules and PEF
energy may be controlled based
on other factors such as volume of molecules 110 to be delivered and/or
delivery/flow rates. For
example, in some embodiments, a predetermined volume of molecules 110 is
delivered to the target tissue
area throughout delivery of PEF energy during a treatment protocol. Thus, the
rate in which it is
delivered is based on the total volume of molecules to be delivered and the
predetermined treatment time.
In other embodiments, a predetermined volume of molecules is delivered during
a first portion of the
-42-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
energy delivery, such as the first 25-33% of energy delivery, and then no
molecules arc delivered for thc
remainder of the treatment. In other embodiments, half of a predetermined
volume of molecules is
delivered during a first portion of energy delivery, such as the first 25% of
energy delivery, and half of
the predetermined volume is delivered during a second portion of the energy
delivery, such as the last
25% of energy delivery. In each of these scenarios, the delivery rate is based
on a particular volume of
molecules and a particular amount of treatment time. It can be inferred that
the molecules would be
delivered with the slowest flow rate in the example wherein the molecules were
delivered throughout the
entire treatment protocol. Likewise, the fastest flow rate would occur in the
example wherein the
molecules were delivered over the first 25-33% of the energy delivery and then
not delivered for the
remainder of the treatment.
[002521 In some embodiments, a user manually delivers the molecules (e.g. by
local injection, regional
injection, systemic infusion, etc.) and activates the generator to deliver the
PEF energy (e.g. by
footswitch). In such embodiments, timing and coordination is achieved by the
user alone or with the
assistance of various components, such as timers, sensors, alerts, data
feedback, etc.
[002531 In other embodiments, the PEF energy is delivered in response to one
or more components,
such as one or more sensors, one or more timers, one or more monitors, a
combination, etc. In some
embodiments, a controller is provided that is configured to control delivery
of the pulsed electric field
energy in response to the one or more components. Example controllers include
a switch box, a delivery
control board, a relay system, a dispatch unit, a microcontroller, a molecular
distribution control board, a
molecule control system, a fluid control system, a fluid control valve, a
molecular fluid servosystem, to
name a few. The controller may be included in or separate from the generator
and functions in
conjunction with the generator so as to control the PEF energy delivery. In
some embodiments, the
controller utilizes one or more components wherein the one or more components
comprises a sensor that
senses a flow rate of molecules being delivered to the patient. In other
embodiments, the controller
utilizes one or more components wherein the one or more components comprises a
sensor that senses
pressure of a syringe pump configured to deliver molecules to the patient. In
other embodiments, the
controller utilizes one or more components wherein the one or more components
comprises a timer and
wherein the controller causes delivery of the pulsed electric field energy at
a predetermined time after
commencement of delivery of molecules to the target tissue area.
[002541 As related to the examples herein above, in some embodiments the
controller causes delivery
of the pulsed electric field energy throughout delivery of molecules to the
target tissue area. In the
embodiment wherein a predetermined volume of molecules is delivered during a
first portion of the
energy delivery, such as the first 25-33% of energy delivery, and then no
molecules are delivered for the
remainder of the treatment, the controller may cause delivery of the pulsed
electric field energy
throughout delivery of molecules to the target tissue area and then continue
delivery of the pulsed electric
field energy for a period 200-300% longer than the delivery of molecules. In
the embodiment wherein
half of a predetermined volume of molecules is delivered during a first
portion, such as the first 25% of
-43 -
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
energy delivery, and half of the predetermined volume is delivered during a
later portion, such as the last
25% of energy delivery, the controller may cause delivery of the pulsed
electric field energy throughout
an additional delivery of molecules that occurs at a time period after the
initial delivery of molecules.
[00255] It may be appreciated that in some embodiments the PEF energy and the
molecules 110 are
delivered by separate devices and in other embodiments the PEF energy and the
molecules 110 are
delivered by the same device. Thus, in some embodiments, the energy delivery
device 102 is configured
to deliver energy to a target tissue area and configured to deliver a
plurality of molecules to the target
tissue area. In such embodiments, the energy may be delivered through an
energy delivery body 108 and
the molecules 110 may be delivered through a lumen and a port near the distal
end of the device 102. In
some embodiments, the molecules 110 are stored in a reservoir, pump or syringe
separate from the device
102 and connectable with the lumen, and in other embodiments the molecules 110
are stored in a
reservoir within the device 102 connected with the lumen or directly to the
port.
Alternative Device Designs
[00256] The energy may be delivered by a variety of energy delivery devices
102. Typically, the
energy delivery device 102 comprises a flexible elongate shaft having a distal
end, capable of being
advanced to the target tissue within the body, and an energy delivery body 108
disposed near the distal
end. The energy delivery body 108 comprises one or more electrodes that
delivers the energy to the
target tissue.
[00257] In some embodiments, the molecules 110 and the energy are delivered by
the energy delivery
device 102. This is in contrast to system delivery of the molecules 110
described and illustrated in
relation to Figs. 5A-5C. In this instance, the induced extravasation may
create an improved (e.g. more
uniform) distribution of the molecules throughout the target treatment area
and/or trap the molecules 110
in the target tissue area so that the molecules are at least temporarily
resisted from diluting away.
[00258] Figs. 21A-21B illustrate an energy delivery device 102 having an
energy delivery body 108
having a needle shape. The tip of the needle shape is able to penetrate
similarly to a needle and deliver
molecules 110 through its internal lumen. In addition, the energy delivery
body 108 is electrically
insulated with an insulation layer 504 except for the tip of the needle shape
which acts as an electrode.
Fig. 21A illustrates direct injection of molecules 110 to a target tissue
through the energy delivery body
108. Again, the target tissue is illustrated as cells C (not to scale). The
tip is inserted in or near the target
tissue so that the injected molecules 110 are able to bathe the target tissue
and optionally dwells for
biodistribution. Referring to Fig. 21B, PEF energy is then delivered to the
target tissue from the energy
delivery body 108 as indicated by wavy lines 502. When the PEF energy is
conditioning PEF, the result
is local edema. When the PEF energy is therapeutic PEF, the energy assists in
uptake of the molecules
110 into the cells C or influences the effect of the molecules 110 on the
cells.
[00259] Fig. 22 illustrates an energy delivery device 102 comprising a shaft
106 having an energy
delivery body 108 near its distal end, wherein the energy delivery body 108
comprises a plurality of tines
600. Typically, the tines 600 have a pointed shape so as to penetrate tissue.
Likewise, the tines 600
-44-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
typically extend laterally outward from the shaft 106, and in some embodiments
thc tines 600 are
disposed circumferentially around the shaft 106. It may be appreciated that in
some embodiments, the
tines 600 are disposed on a side of the shaft 106, such aligned in a row. In
some embodiments, the tines
600 extend the same distance from the shaft 106 and in other embodiments the
tines 600 extend a varied
distance. It may be appreciated that in some embodiments, the extension of at
least some of the tines 600
from the shaft 106 is adjustable.
[00260] Typically, each tine 600 delivers molecules 110 and/or energy
therefrom. In some
embodiments, molecules 110 are delivered from the tip 601 of the tine 600 and
in other embodiments
molecules 110 are delivered from delivery ports 602 along the tine 600. In
some embodiments, the tines
600 are energizable together (so as to act as a single electrode) or at least
some of the tines 600 are
individually energizable (so as to act in bipolar pairs).
[00261] In this embodiment, the shaft 106 has three sections, a first section
106a, a second section
106b and a third section 106c. As illustrated in Fig. 22, the first section
106a is distal to the second
section 106b which is distal to the third section 106c. Each section 106a,
106b, 106c may be insulated or
non-insulated so as to create a variety of different electrode combinations.
This may allow various
electric field shapes and/or direct the electric field in desired directions.
It may also be appreciated that in
some embodiments, at least a portion of at least one tine 600 is insulated so
as to direct the energy
emanating therefrom. Overall, the tines 600 are often able to deliver
molecules 110 and/or energy to a
larger volume of target tissue with a single placement of the energy delivery
device 102 than with a
device 102 having an energy delivery device 108 comprising a single needle.
[00262] Fig. 23 illustrates an energy delivery device 102 comprising an energy
delivery body 108
having a basket shape configured for treating target tissue endoluminally.
Here the target tissue
comprises cells C disposed near a wall W of a body lumen, particularly
wrapping at least partially
circumferentially around the body lumen. In this embodiment, the energy
delivery body 108 is comprised
of a plurality of wires or ribbons 120 forming a spiral-shaped basket serving
as an electrode. In some
embodiments, the energy delivery body 108 is self-expandable and delivered to
a targeted area in a
collapsed configuration. This collapsed configuration can be achieved, for
example, by placing a sheath
over the energy delivery body 108. Retraction of the sheath or advancement of
the energy delivery body
108 from the sheath allows the energy delivery body 108 to self-expand. In
other embodiments, the
energy delivery device 102 includes a handle having an energy delivery body
manipulation knob wherein
movement of the knob causes expansion or retraction/collapse of the basket-
shaped electrode. The
basket-shaped electrode is expandable within a body lumen or passageway
(naturally occurring or created
within the body) so as to contact at least a portion of the wall W of the
lumen. Molecules 110 are
delivered from the energy delivery device 102, such as through a distal end
port 510 and/or through
various side ports 512 along a shaft 106 of the device 102, such as within the
basket-shaped electrode, as
illustrated in Fig. 23. The molecules 110 are able to bathe the target tissue
and optionally dwell for
biodistribution. Conditioning PEF energy is delivered to the target tissue
from the energy delivery body
-45-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
108 as indicated by wavy lines 502. This causes induced extravasation in the
local area surrounding the
lumen. Therapeutic PEF energy assists in uptake of the molecules 110 into the
cells C or influences the
effect of the molecules 110 on the cells.
[00263] Fig. 24 illustrates another embodiment of an energy delivery device
102 comprising an energy
delivery body 108 having a shape configured for treating target tissue
endoluminally. In this
embodiment, the energy delivery body 108 comprises at least two protrusions
514, each protrusion
extending radially outwardly so as to contact an inner luminal wall W. It may
be appreciated that
although a single protrusion may be present, typically two protrusions are
present to apply substantially
opposing forces to the walls the lumen. In the embodiment of Fig. 24, three
protrusions 514 are present.
In some embodiments, each protrusion 514 is formed by a wire or ribbon which
acts as an electrode and
bends or bows radially outward from the longitudinal axis or shaft 106 of the
delivery device 102. In this
embodiment, the protrusions 514 together act as a single electrode. However,
in other embodiments, one
or more protrusions 514 are independently energizeable so as to act as
multiple electrodes (e.g. as one or
more bipolar pairs). The protrusions 514 may be comprised of a variety of
suitable materials so as to act
as an electrode, such as stainless steel, spring steel, or other alloys, and
may be, for example, round wires
or ribbon. In some embodiments, a portion of the protrusions 514 are insulated
with a segment of
insulation, such as a polymer (e.g., PET, polyether block amide, polyimide).
For example, in some
embodiments at least a portion of the proximal and distal ends of the energy
delivery body 108 are
insulated to direct the energy laterally, toward the walls W.
[00264] In some embodiments, the energy delivery body 108 of Fig. 24 is self-
expandable and
delivered to a targeted area in a collapsed configuration. The protrusions bow
outwardly during
expansion within a body lumen or passageway (naturally occurring or created
within the body) so as to
contact at least a portion of the wall W of the lumen. Molecules 110 is
delivered from the energy delivery
device 102, such as through a port 516 within the energy delivery body 108, as
illustrated in Fig. 24. The
molecules 110 are able to bathe the target tissue and optionally dwell for
biodistribution. PEF energy is
then delivered to the target tissue from the energy delivery body 108 as
indicated by wavy lines 502. The
PEF energy delivers the molecules 110 into the cells C.
[00265] Fig. 25 illustrates another embodiment of an energy delivery device
102 comprising an energy
delivery body 108 having a shape configured for treating target tissue
endoluminally. In this
embodiment, the energy delivery body 108 comprises an expandable member 518,
such as an inflatable
balloon, having an electrode 520 mounted thereon or incorporated therein. The
energy delivery body 108
is delivered to a targeted area in a collapsed configuration. In this
embodiment, the electrode 520 has the
form of a pad having a relatively broad surface area and thin cross-section.
The pad shape provides a
broader surface area than other shapes, such as a wire shape. Each electrode
520 is connected with a
conduction wire 522 which electrically connects the electrode 520 with the
generator. In this
embodiment, the three electrodes 520 are visible, however it may be
appreciated that additional electrodes
may be present around the expandable member 518. It may be appreciated that
any number of electrodes
-46-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
520 may be present, acting as a single electrode or acting independently or in
combination. Placement of
the electrodes 520 and/or selective energizing of the electrodes 520 may
direct the energy toward
particular target locations. In some embodiments, the electrodes 520 are
comprised of flexible circuit
pads or other materials attached to the expandable member 518 or formed into
the expandable member
518. In some embodiments, the electrodes 520 are distributed radially around
the circumference of the
expandable member 518 and/or distributed longitudinally along the length of
the expandable member
518. Such designs may facilitate improved deployment and retraction qualities,
easing user operation and
compatibility with introducer lumens.
[00266] Upon expansion of the expandable member, one or more of the electrodes
520 are positioned
so as to contact at least a portion of the wall W of the lumen. Molecules 110
arc delivered from the
energy delivery device 102, such as through a distal end port 510, as
illustrated in Fig. 25. The molecules
110 are able to bathe the target tissue and optionally dwell for
biodistribution. Conditioning PEF energy
is delivered to the target tissue from the energy delivery body 108 as
indicated by wavy lines 502. This
causes induced edema in the local area surrounding the lumen. Therapeutic PEF
energy assists in uptake
of the molecules 110 into the cells C or influences the effect of the
molecules 110 on the cells.
[00267] Fig. 26 illustrates another embodiment of an energy delivery device
102. Here the energy
delivery body 108 has a finger-tip shape configured to contact an inner lumen
wall W. In this
embodiment, the energy delivery device 102 has an elongate shaft 106 and
finger-tip electrode 530
disposed at its distal tip. The finger-tip electrode 530 is positionablc
against the portion of the lumen wall
W near the target tissue cells C. The molecules 110 may be delivered by any
suitable method, such as
systemically, regionally or locally, such as by injection through a separate
device or through the energy
delivery device 102. Fig. 26 illustrates delivery of molecules 110 through the
finger tip electrode 530.
Conditioning PEF energy is delivered to the target tissue from the finger tip
electrode 530 as indicated by
wavy lines 502. This causes induced extravasation in the local area
surrounding the lumen. Therapeutic
PEF energy assists in uptake of the molecules 110 into the cells C or
influences the effect of the
molecules 110 on the cells.
[00268] It may be appreciated that in some embodiments, PEF energy is
delivered to a conductive fluid
(e.g. blood, saline, etc.) in contact with the target tissue. Thus, the energy
is able to pass through the
conductive fluid to the target tissue for delivery. In other embodiments,
delivery of energy to the
conductive fluid promotes delivery of molecules into the cells of the fluid
itself, such as delivery into
leukocytes in blood.
[00269] It may be appreciated that although a variety of embodiments described
herein include
multiple steps or methodologies, such as extravasation, molecule delivery,
transfection, ablation, etc.,
each may be utilized alone or in any combination with any other method. For
example, extravasation
may be induced for a variety of purposes with or without follow-on therapy. It
may be appreciated that
PEF energy may be utilized to improve diffusion and distribution of molecules
amongst tissue for a
variety of therapies, many of which do not involve ablation or further
therapy. For example, when
-47-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
delivering agents via inhalation, PEF energy may be delivered before, during
or after inhalation to cause
the agents to reach deeper cells within the lung anatomy, such as smooth
muscle cells, cartilage, etc.
Likewise, when anti-epilepsy drugs are delivered by IV, local injection or via
the cerebrospinal fluid, PEF
energy may be delivered to cause better distribution of the drug amongst the
foci of where the seizures are
starting. These are just a few examples of improved delivery of an agent to
treat a condition or disease.
[00270] Likewise, a variety of therapies and combinations of therapies may be
provided to a patient
without extravasation induction. Further, certain effects of portions of the
therapy may still ensue
regardless of the presence of particular steps in the therapy. Likewise, a
variety of treatment aspects
described herein may ensue without the inclusion of all of the steps of the
methodology. For example,
steps ensuing after the creation of a debris field DF (Figs. 8A-8B) would
occur regardless of the use of
induced extravasation in the procedure. Thus, clearing of the debris field DF
and the resultant immune
response, including the effect on any metastases, would occur regardless of
the use of induced
extravasation. However, the induced extravasation may affect the extent of
these effects, such as by
improving the size, depth, components, etc., of the debris field.
[00271] The above detailed description includes references to the accompanying
drawings, which form
a part of the detailed description. The drawings show, by way of illustration,
specific embodiments in
which the invention can be practiced. These embodiments are also referred to
herein as -examples."
Such examples can include elements in addition to those shown or described.
However, the present
inventors also contemplate examples in which only those elements shown or
described arc provided.
Moreover, the present inventors also contemplate examples using any
combination or permutation of
those elements shown or described (or one or more aspects thereof), either
with respect to a particular
example (or one or more aspects thereof), or with respect to other examples
(or one or more aspccts
thereof) shown or described herein.
[00272] In the event of inconsistent usages between this document and any
documents so incorporated
by reference, the usage in this document controls.
[00273] In this document, the tenns -a" or -an" are used, as is common in
patent documents, to include
one or more than one, independent of any other instances or usages of "at
least one" or "one or more." In
this document, the term "or" is used to refer to a nonexclusive or, such that
"A or B" includes "A but not
B," -B but not A," and -A and B," unless otherwise indicated. In this
document, the terms -including"
and "in which" are used as the plain-English equivalents of the respective
terms "comprising" and
"wherein." Also, in the following claims, the terms "including" and
"comprising" are open-ended, that is,
a system, device, article, composition, formulation, or process that includes
elements in addition to those
listed after such a term in a claim are still deemed to fall within the scope
of that claim. Moreover, in the
following claims, the terms "first," "second," and "third," etc. arc used
merely as labels, and are not
intended to impose numerical requirements on their objects.
[00274] The above description is intended to be illustrative, and not
restrictive. For example, the
above-described examples (or one or more aspects thereof) may be used in
combination with each other.
-48-
CA 03222048 2023- 12- 8
WO 2022/260723
PCT/US2022/015217
Other embodiments can be used, such as by one of ordinary skill in the art
upon reviewing the above
description. The Abstract is provided to comply with 37 C.F.R. 1.72(b), to
allow the reader to quickly
ascertain the nature of the technical disclosure. It is submitted with the
understanding that it will not be
used to interpret or limit the scope or meaning of the claims. Also, in the
above Detailed Description,
various features may be grouped together to streamline the disclosure. This
should not be interpreted as
intending that an unclaimed disclosed feature is essential to any claim.
Rather, inventive subject matter
may lie in less than all features of a particular disclosed embodiment. Thus,
the following claims are
hereby incorporated into the Detailed Description as examples or embodiments,
with each claim standing
on its own as a separate embodiment, and it is contemplated that such
embodiments can be combined
with each other in various combinations or permutations. The scope of the
invention should be
determined with reference to the appended claims, along with the full scope of
equivalents to which such
claims are entitled.
-49-
CA 03222048 2023- 12- 8
